|
特拉华州
|
| |
13-1840497
|
|
|
(州或其他司法管辖区
成立公司或组织) |
| |
(税务局雇主
标识号) |
|
|
Glenpointe Center East,3楼
弗兰克·W·伯尔大道300号,21号套房 新泽西州蒂内克 |
| |
07666-6712 |
|
|
(主要执行办公室地址)
|
| |
(邮政编码)
|
|
|
每个班级的标题
|
| |
交易代码
|
| |
注册的每个交易所的名称
|
|
|
A类普通股,0.0001美元
每股面值 |
| |
PAHC
|
| |
纳斯达克股票市场
|
|
|
大型加速文件服务器
☐
|
| |
加速文件管理器
|
|
|
非加速文件管理器
☐
|
| |
较小的报告公司
☐
|
|
|
新兴成长型公司
☐
|
| | | |
| | |
第
页
|
| |||
前瞻性陈述
|
| | | | 3 | | |
市场排名等行业数据
|
| | | | 4 | | |
商标、服务标记和商品名称
|
| | | | 5 | | |
第一部分 | | | | | | | |
第1项。
业务
|
| | | | 6 | | |
第1A项。
风险因素
|
| | | | 28 | | |
项目1B。
未解决的员工意见
|
| | | | 54 | | |
第2项。
属性
|
| | | | 54 | | |
第3项。
法律诉讼
|
| | | | 54 | | |
第4项。
煤矿安全信息披露
|
| | | | 55 | | |
第二部分 | | | | | | | |
第5项。
注册人普通股、相关股东事项和发行人购买股权证券的市场
|
| | | | 56 | | |
第6项。
选定的财务数据
|
| | | | 57 | | |
第7项。
管理层对财务状况和经营成果的讨论和分析
|
| | | | 60 | | |
项目7A。
关于市场风险的定量和定性披露
|
| | | | 81 | | |
第8项。
财务报表及辅助数据
|
| | | | 83 | | |
第9项。
会计在会计和财务披露方面的变更和分歧
|
| | | | 123 | | |
第9A项。
控制程序
|
| | | | 123 | | |
第9B项。
其他信息
|
| | | | 125 | | |
第三部分 | | | | | | | |
第10项。
董事、高管和公司治理
|
| | | | 126 | | |
物品编号11。
高管薪酬
|
| | | | 126 | | |
第12项。
某些受益所有者的担保所有权以及管理层和相关股东事宜
|
| | | | 126 | | |
第13项。
某些关系和相关交易,以及董事独立性
|
| | | | 126 | | |
第14项。
主要会计费和服务
|
| | | | 126 | | |
第四部分 | | | | | | | |
物品:15。
展品,财务报表明细表
|
| | | | 127 | | |
签名
|
| | | | 131 | | |
| | |
细分市场
|
| |
更改
|
| |
占总数的百分比
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||
截至2019年6月30日的年度
|
| |
2020
|
| |
2019
|
| |
2018
|
| |
2020 / 2019
|
| |
2019 / 2018
|
| |
2020
|
| |
2019
|
| |
2018
|
| ||||||||||||||||||||||||||||||||||||
| | | | | | | | |
(百万美元)
|
| | | | | | | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||
动物健康
|
| | | $ | 527 | | | | | $ | 532 | | | | | $ | 532 | | | | | $ | (5) | | | | |
|
(1)%
|
| | | | $ | 0 | | | | |
|
0%
|
| | | |
|
66%
|
| | | |
|
64%
|
| | | |
|
65%
|
| |
矿物质营养
|
| | | | 214 | | | | | | 234 | | | | | | 235 | | | | | | (19) | | | | | | (8)% | | | | | | (1) | | | | |
|
(0)%
|
| | | |
|
27%
|
| | | |
|
28%
|
| | | |
|
29%
|
| |
性能产品
|
| | | | 59 | | | | | | 62 | | | | | | 53 | | | | | | (3) | | | | |
|
(5)%
|
| | | | | 9 | | | | |
|
17%
|
| | | |
|
7%
|
| | | |
|
8%
|
| | | |
|
7%
|
| |
合计
|
| | | $ | 800 | | | | | $ | 828 | | | | | $ | 820 | | | | | $ | (28) | | | | |
|
(3)%
|
| | | | $ | 8 | | | | |
|
1%
|
| | | | | | | | | | | | | | | | | | | |
|
| | |
种
|
| |
更改
|
| |
占总数的百分比
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||
截至2019年6月30日的年度
|
| |
2020
|
| |
2019
|
| |
2018
|
| |
2020 / 2019
|
| |
2019 / 2018
|
| |
2020
|
| |
2019
|
| |
2018
|
| ||||||||||||||||||||||||||||||||||||
| | | | | | | | |
(百万美元)
|
| | | | | | | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||
家禽
|
| | | $ | 301 | | | | | $ | 316 | | | | | $ | 321 | | | | | $ | (15) | | | | |
|
(5)%
|
| | | | $ | (5) | | | | |
|
(2)%
|
| | | |
|
38%
|
| | | |
|
38%
|
| | | |
|
39%
|
| |
奶制品
|
| | | | 163 | | | | | | 170 | | | | | | 177 | | | | | | (7) | | | | |
|
(4)%
|
| | | | | (7) | | | | |
|
(4)%
|
| | | |
|
20%
|
| | | |
|
21%
|
| | | |
|
22%
|
| |
头牛
|
| | | | 94 | | | | | | 88 | | | | | | 80 | | | | | | 6 | | | | |
|
7%
|
| | | | | 8 | | | | |
|
10%
|
| | | |
|
12%
|
| | | |
|
11%
|
| | | |
|
10%
|
| |
猪
|
| | | | 81 | | | | | | 101 | | | | | | 100 | | | | | | (20) | | | | |
|
(20)%
|
| | | | | 1 | | | | |
|
1%
|
| | | |
|
10%
|
| | | |
|
12%
|
| | | |
|
12%
|
| |
其他(1) | | | | | 161 | | | | | | 153 | | | | | | 142 | | | | | | 8 | | | | |
|
5%
|
| | | | | 11 | | | | |
|
8%
|
| | | |
|
20%
|
| | | |
|
18%
|
| | | |
|
17%
|
| |
合计
|
| | | $ | 800 | | | | | $ | 828 | | | | | $ | 820 | | | | | $ | (28) | | | | |
|
(3)%
|
| | | | $ | 8 | | | | |
|
1%
|
| | | | | | | | | | | | | | | | | | | |
|
| | |
地区(2)
|
| |
更改
|
| |
占总数的百分比
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||
截至2019年6月30日的年度
|
| |
2020
|
| |
2019
|
| |
2018
|
| |
2020 / 2019
|
| |
2019 / 2018
|
| |
2020
|
| |
2019
|
| |
2018
|
| ||||||||||||||||||||||||||||||||||||
| | | | | | | | |
(百万美元)
|
| | | | | | | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||
美国
|
| | | $ | 472 | | | | | $ | 481 | | | | | $ | 491 | | | | | $ | (9) | | | | |
|
(2)%
|
| | | | $ | (10) | | | | |
|
(2)%
|
| | | |
|
59%
|
| | | |
|
58%
|
| | | |
|
60%
|
| |
拉丁美洲和加拿大
|
| | | | 159 | | | | | | 152 | | | | | | 143 | | | | | | 7 | | | | |
|
5%
|
| | | | | 9 | | | | |
|
6%
|
| | | |
|
20%
|
| | | |
|
18%
|
| | | |
|
17%
|
| |
欧洲、中东和非洲
|
| | | | 112 | | | | | | 105 | | | | | | 110 | | | | | | 7 | | | | |
|
7%
|
| | | | | (5) | | | | |
|
(5)%
|
| | | |
|
14%
|
| | | |
|
13%
|
| | | |
|
13%
|
| |
亚太地区
|
| | | | 57 | | | | | | 90 | | | | | | 76 | | | | | | (33) | | | | |
|
(37)%
|
| | | | | 14 | | | | |
|
18%
|
| | | |
|
7%
|
| | | |
|
11%
|
| | | |
|
9%
|
| |
合计
|
| | | $ | 800 | | | | | $ | 828 | | | | | $ | 820 | | | | | $ | (28) | | | | |
|
(3)%
|
| | | | $ | 8 | | | | |
|
1%
|
| | | | | | | | | | | | | | | | | | | |
| | |
调整后EBITDA(1)
|
| |
更改
|
| |
占总数(2)的百分比
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||
截至2019年6月30日的年度
|
| |
2020
|
| |
2019
|
| |
2018
|
| |
2020 / 2019
|
| |
2019 / 2018
|
| |
2020
|
| |
2019
|
| |
2018
|
| ||||||||||||||||||||||||||||||||||||
| | | | | | | | |
(百万美元)
|
| | | | | | | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||
动物健康
|
| | | $ | 123 | | | | | $ | 136 | | | | | $ | 142 | | | | | $ | (13) | | | | |
|
(10)%
|
| | | | $ | (6) | | | | |
|
(4)%
|
| | | |
|
87%
|
| | | |
|
87%
|
| | | |
|
87%
|
| |
矿物质营养
|
| | | | 15 | | | | | | 16 | | | | | | 19 | | | | | | (1) | | | | |
|
(7)%
|
| | | | | (3) | | | | |
|
(15)%
|
| | | |
|
10%
|
| | | |
|
10%
|
| | | |
|
11%
|
| |
性能产品
|
| | | | 5 | | | | | | 5 | | | | | | 2 | | | | | | (0) | | | | |
|
(4)%
|
| | | | | 3 | | | | |
|
151%
|
| | | |
|
3%
|
| | | |
|
3%
|
| | | |
|
1%
|
| |
企业
|
| | | | (40) | | | | | | (38) | | | | | | (33) | | | | | | (2) | | | | |
|
*
|
| | | | | (5) | | | | |
|
*
|
| | | | | | | | | | | | | | | | | | | |
合计
|
| | | $ | 102 | | | | | $ | 118 | | | | | $ | 129 | | | | | $ | (16) | | | | |
|
(13)%
|
| | | | $ | (11) | | | | |
|
(8)%
|
| | | | | | | | | | | | | | | | | | | |
| | |
可确认净资产
|
| |
更改
|
| |
占总数的百分比
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||
截至6月30日
|
| |
2020
|
| |
2019
|
| |
2018
|
| |
2020 / 2019
|
| |
2019 / 2018
|
| |
2020
|
| |
2019
|
| |
2018
|
| ||||||||||||||||||||||||||||||||||||
| | | | | | | | |
(百万美元)
|
| | | | | | | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||
动物健康
|
| | | $ | 561 | | | | | $ | 509 | | | | | $ | 456 | | | | | $ | 52 | | | | |
|
10%
|
| | | | $ | 53 | | | | |
|
12%
|
| | | |
|
71%
|
| | | |
|
70%
|
| | | |
|
68%
|
| |
矿物质营养
|
| | | | 66 | | | | | | 68 | | | | | | 70 | | | | | | (2) | | | | |
|
(2)%
|
| | | | | (2) | | | | |
|
(3)%
|
| | | |
|
8%
|
| | | |
|
9%
|
| | | |
|
10%
|
| |
性能产品
|
| | | | 31 | | | | | | 33 | | | | | | 24 | | | | | | (2) | | | | |
|
(6)%
|
| | | | | 9 | | | | |
|
37%
|
| | | |
|
4%
|
| | | |
|
5%
|
| | | |
|
4%
|
| |
企业
|
| | | | 127 | | | | | | 117 | | | | | | 122 | | | | | | 10 | | | | |
|
8%
|
| | | | | (5) | | | | |
|
(4)%
|
| | | |
|
16%
|
| | | |
|
16%
|
| | | |
|
18%
|
| |
合计
|
| | | $ | 784 | | | | | $ | 727 | | | | | $ | 672 | | | | | $ | 58 | | | | |
|
8%
|
| | | | $ | 54 | | | | |
|
8%
|
| | | | | | | | | | | | | | | | | | | |
| | |
产品组
|
| |
更改
|
| |
占总数的百分比
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||
截至6月30日的年度
|
| |
2020
|
| |
2019
|
| |
2018
|
| |
2020 / 2019
|
| |
2019 / 2018
|
| |
2020
|
| |
2019
|
| |
2018
|
| ||||||||||||||||||||||||||||||||||||
| | | | | | | | |
(百万美元)
|
| | | | | | | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||
MFA和其他
|
| | | $ | 322 | | | | | $ | 350 | | | | | $ | 337 | | | | | $ | (28) | | | | |
|
(8)%
|
| | | | $ | 13 | | | | |
|
4%
|
| | | |
|
61%
|
| | | |
|
66%
|
| | | |
|
63%
|
| |
营养特产
|
| | | | 129 | | | | | | 113 | | | | | | 123 | | | | | | 16 | | | | |
|
14%
|
| | | | | (10) | | | | |
|
(8)%
|
| | | |
|
25%
|
| | | |
|
21%
|
| | | |
|
23%
|
| |
疫苗
|
| | | | 75 | | | | | | 68 | | | | | | 72 | | | | | | 7 | | | | |
|
10%
|
| | | | | (4) | | | | |
|
(5)%
|
| | | |
|
14%
|
| | | |
|
13%
|
| | | |
|
14%
|
| |
动物健康
|
| | | $ | 527 | | | | | $ | 532 | | | | | $ | 532 | | | | | $ | (5) | | | | |
|
(1)%
|
| | | | $ | (0) | | | | |
|
(0)%
|
| | | | | | | | | | | | | | | | | | | |
|
| | |
地区(1)
|
| |
更改
|
| |
占总数的百分比
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||
截至6月30日的年度
|
| |
2020
|
| |
2019
|
| |
2018
|
| |
2020 / 2019
|
| |
2019 / 2018
|
| |
2020
|
| |
2019
|
| |
2018
|
| ||||||||||||||||||||||||||||||||||||
| | | | | | | | |
(百万美元)
|
| | | | | | | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||
美国
|
| | | $ | 214 | | | | | $ | 199 | | | | | $ | 220 | | | | | $ | 15 | | | | |
|
8%
|
| | | | $ | (21) | | | | |
|
(10)%
|
| | | |
|
41%
|
| | | |
|
37%
|
| | | |
|
41%
|
| |
拉丁美洲和加拿大
|
| | | | 148 | | | | | | 142 | | | | | | 129 | | | | | | 6 | | | | |
|
4%
|
| | | | | 13 | | | | |
|
10%
|
| | | |
|
28%
|
| | | |
|
27%
|
| | | |
|
24%
|
| |
欧洲、中东和非洲
|
| | | | 109 | | | | | | 103 | | | | | | 108 | | | | | | 6 | | | | |
|
6%
|
| | | | | (5) | | | | |
|
(5)%
|
| | | |
|
21%
|
| | | |
|
19%
|
| | | |
|
20%
|
| |
亚太地区
|
| | | | 56 | | | | | | 88 | | | | | | 75 | | | | | | (32) | | | | |
|
(36)%
|
| | | | | 13 | | | | |
|
17%
|
| | | |
|
11%
|
| | | |
|
17%
|
| | | |
|
14%
|
| |
合计
|
| | | $ | 527 | | | | | $ | 532 | | | | | $ | 532 | | | | | $ | (5) | | | | |
|
(1)%
|
| | | | $ | — | | | | |
|
0%
|
| | | | | | | | | | | | | | | | | | | |
产品
|
| |
活性成分
|
| |
的市场准入
活性成分 |
| |
说明
|
|
土霉素®/TM-50®/TM-100™ | | | 土霉素 | | |
1951
|
| | 多种用途的抗菌剂 | |
尼加拉瓜® | | | 尼加拉瓜巴津 | | |
1954
|
| | 家禽抗球虫药 | |
氨丙胺 | | | 氨丙胺 | | |
1960
|
| | 家禽和牛的抗球虫药 | |
Bloat Guard® | | | 聚二氢呋喃 | | |
1967
|
| | 牛的防胀治疗 | |
Banminth® | | | 酒石酸吡喃酮 | | |
1972
|
| | 牲畜驱虫剂 | |
Mecadox® | | | 卡巴多 | | |
1972
|
| | 猪肠道病原体,包括沙门氏菌病和痢疾的抗菌药物 | |
斯塔法克®/埃斯卡林™/V-MAX® | | | 维吉尼亚霉素 | | |
1975
|
| | 用于预防和控制家禽、猪和牛疾病的抗菌剂 | |
Coxistac™/Posistac™ | | | 盐霉素 | | |
1979
|
| |
家禽、牛和猪的抗球虫药
|
|
Rumatel® | | | 酒石酸莫兰特 | | |
1981
|
| | 牲畜驱虫剂 | |
Cerditac™/CerdiMix™ | | | 奥苯达唑 | | |
1982
|
| | 牲畜驱虫剂 | |
Aviax® | | | 阿米达霉素 | | |
1995
|
| | 家禽抗球虫药 | |
新土霉素®/ NEO-TM™ |
| | 土霉素+新霉素 | | |
1999
|
| | 多种用途的两种抗菌药组合 | |
Aviax®Plus/Avi-Carb® | | | 阿米达霉素+尼加拉瓜巴嗪 | | |
2010
|
| | 家禽抗球虫药 | |
产品
|
| |
市场
条目 |
| |
说明
|
|
AB20® | | |
1989
|
| | 提高整体饲料质量的天然流动剂 | |
产品
|
| |
市场
条目 |
| |
说明
|
|
动画® | | |
1999
|
| | 在关键过渡期保持奶牛适当的血钙水平 | |
OmniGen® | | |
2004
|
| |
优化奶牛免疫功能,提高生产效率
|
|
Provia 6086™ | | |
2013
|
| | 各类家畜直接饲喂微生物(凝乳杆菌) | |
Magni-Phi® | | |
2015
|
| | 有助于改善肠道健康和免疫反应的专利混合物,这可能会提高家禽对营养的吸收和利用 | |
蜂窝状酵母解决方案® | | |
2017
|
| | 各类家畜专用酵母培养产品,帮助改善消化健康 | |
Provia Prime™ | | |
2019
|
| | 四联直饲微生物优化家禽肠道健康 | |
产品
|
| |
市场
条目 |
| |
说明
|
|
V.H.® | | |
1974
|
| | 预防家禽新城疫的活疫苗 | |
特制疫苗 | | |
1982
|
| | 针对家禽、猪和牛的细菌性或病毒性疾病的自体疫苗 | |
MVP辅助剂® | | |
1982
|
| | 增强疫苗免疫应答的兽用疫苗成分 | |
TAbic®M.B. | | |
2004
|
| | 预防家禽传染性法氏囊病的活疫苗 | |
MJPRRS® | | |
2007
|
| | 预防猪繁殖与呼吸综合征(PRRS)的自体疫苗 | |
TAbic®IB VAR | | |
2009
|
| | 预防家禽传染性支气管炎变异株1 233A株的活疫苗 | |
TAbic®IB VAR206 | | |
2010
|
| | 预防鸡传染性支气管炎206变异株的活疫苗 | |
MB-1TM | | |
2017
|
| | 预防家禽传染性法氏囊病的孵化活疫苗 | |
Phi-TechTM | | |
2019
|
| | 便携式电子注射设备和软件,可正确交付疫苗和管理信息 | |
个业务部门
|
| |
位置
|
| |
拥有/
租赁 |
| |
近似。平方
素材 |
| |
目的
|
| |||
动物健康 | | | 以色列拜特谢梅什 | | |
拥有/
土地租赁 |
| | | | 78,000 | | | | 制造与研究 | |
动物健康 | | | 巴西布拉甘卡·保利斯塔 | | | 拥有 | | | | | 50,000 | | | | 制造和管理 | |
动物健康 | | | 阿根廷布宜诺斯艾利斯 | | | 拥有 | | | | | 43,000 | | | | 制造和管理 | |
动物健康 | | | 伊利诺伊州Chillicothe市 | | | 拥有 | | | | | 19,000 | | | | 制造 | |
动物健康 | | | 俄勒冈州科瓦利斯 | | | 拥有 | | | | | 5,000 | | | | 调研 | |
动物健康 | | | 巴西瓜鲁霍斯 | | | 拥有 | | | | | 1,294,000 | | | |
制造、销售、预混、
研究和管理 |
|
动物健康 | | | Neot Hovav,以色列 | | |
拥有/ 土地契约 |
| | | | 140,000 | | | | 制造与研究 | |
矿物质营养 | | | 内布拉斯加州奥马哈 | | | 拥有 | | | | | 84,000 | | | | 制造 | |
动物健康 | | | 内布拉斯加州奥马哈 | | | 拥有 | | | | | 43,000 | | | | 制造、销售和研究 | |
动物健康 | | | 佩奇·提克瓦,以色列 | | | 拥有 | | | | | 60,000 | | | | 制造 | |
动物健康和矿物质营养 | | | 伊利诺伊州昆西 | | | 拥有 | | | | | 306,000 | | | | 制造、销售、研究和管理 | |
性能产品
|
| | 加利福尼亚州圣达菲温泉 | | | 拥有 | | | | | 108,000 | | | | 制造 | |
动物健康 | | | 宾夕法尼亚州州立学院 | | | 拥有 | | | | | 13,000 | | | | 调研 | |
动物健康 | | | 明尼苏达州圣保罗 | | | 租赁 | | | | | 5,000 | | | | 调研 | |
动物健康 | | | 佛罗里达州萨拉索塔 | | | 租赁 | | | | | 93,000 | | | | 制造、销售、研究和管理 | |
企业 | | | 新泽西州蒂内克 | | | 租赁 | | | | | 50,000 | | | | 公司和行政部门 | |
截至2019年6月30日的年度
|
| |
2020
|
| |
2019
|
| |
2018
|
| |
2017
|
| |
2016
|
| |||||||||||||||
| | |
(千元,每股除外)
|
| |||||||||||||||||||||||||||
运营结果数据 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
净销售额
|
| | | $ | 800,354 | | | | | $ | 827,995 | | | | | $ | 819,982 | | | | | $ | 764,281 | | | | | $ | 751,526 | | |
销货成本
|
| | | | 543,472 | | | | | | 563,371 | | | | | | 553,103 | | | | | | 516,038 | | | | | | 512,494 | | |
毛利
|
| | | | 256,882 | | | | | | 264,624 | | | | | | 266,879 | | | | | | 248,243 | | | | | | 239,032 | | |
销售、一般和行政费用
|
| | | | 187,688 | | | | | | 181,398 | | | | | | 167,953 | | | | | | 150,309 | | | | | | 153,288 | | |
营业收入
|
| | | | 69,194 | | | | | | 83,226 | | | | | | 98,926 | | | | | | 97,934 | | | | | | 85,744 | | |
利息费用净额
|
| | | | 12,856 | | | | | | 11,776 | | | | | | 11,910 | | | | | | 14,906 | | | | | | 16,592 | | |
外币(收益)亏损,净额
|
| | | | 826 | | | | | | (55) | | | | | | (1,054) | | | | | | (113) | | | | | | (7,609) | | |
债务清偿损失
|
| | | | — | | | | | | — | | | | | | — | | | | | | 2,598 | | | | | | — | | |
所得税前收入
|
| | | | 55,512 | | | | | | 71,505 | | | | | | 88,070 | | | | | | 80,543 | | | | | | 76,761 | | |
所得税拨备(福利)
|
| | | | 21,960 | | | | | | 16,792 | | | | | | 23,187 | | | | | | 15,928 | | | | | | (5,967) | | |
净收入
|
| | | $ | 33,552 | | | | | $ | 54,713 | | | | | $ | 64,883 | | | | | $ | 64,615 | | | | | $ | 82,728 | | |
每股净收益 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
基础版
|
| | | $ | 0.83 | | | | | $ | 1.35 | | | | | $ | 1.61 | | | | | $ | 1.63 | | | | | $ | 2.11 | | |
稀释
|
| | | $ | 0.83 | | | | | $ | 1.35 | | | | | $ | 1.61 | | | | | $ | 1.61 | | | | | $ | 2.07 | | |
加权平均已发行普通股 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
基础版
|
| | | | 40,454 | | | | | | 40,412 | | | | | | 40,181 | | | | | | 39,524 | | | | | | 39,254 | | |
稀释
|
| | | | 40,504 | | | | | | 40,523 | | | | | | 40,385 | | | | | | 40,042 | | | | | | 39,962 | | |
每股股息
|
| | | $ | 0.48 | | | | | $ | 0.46 | | | | | $ | 0.40 | | | | | $ | 0.40 | | | | | $ | 0.40 | | |
其他财务数据 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
调整后EBITDA(1)
|
| | | $ | 102,140 | | | | | $ | 118,037 | | | | | $ | 128,958 | | | | | $ | 120,119 | | | | | $ | 114,060 | | |
经营活动提供的现金(2)
|
| | | | 59,348 | | | | | | 47,169 | | | | | | 70,008 | | | | | | 98,385 | | | | | | 37,218 | | |
资本支出
|
| | | | 34,045 | | | | | | 29,891 | | | | | | 18,548 | | | | | | 20,880 | | | | | | 36,352 | | |
截至2019年6月30日的年度
|
| |
2020
|
| |
2019
|
| |
2018
|
| |
2017
|
| |
2016
|
| |||||||||||||||
| | |
(千)
|
| |||||||||||||||||||||||||||
资产负债表数据 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
现金和现金等价物以及短期投资
|
| | | $ | 91,343 | | | | | $ | 81,573 | | | | | $ | 79,168 | | | | | $ | 56,083 | | | | | $ | 33,605 | | |
营运资金(3)
|
| | | | 222,006 | | | | | | 242,902 | | | | | | 205,651 | | | | | | 198,036 | | | | | | 203,356 | | |
总资产
|
| | | | 784,100 | | | | | | 726,671 | | | | | | 671,679 | | | | | | 623,397 | | | | | | 607,835 | | |
总债务(4)
|
| | | | 387,007 | | | | | | 326,175 | | | | | | 312,381 | | | | | | 313,141 | | | | | | 350,172 | | |
长期债务和其他负债
|
| | | | 438,658 | | | | | | 356,429 | | | | | | 343,504 | | | | | | 356,444 | | | | | | 408,578 | | |
股东权益总额
|
| | | | 188,204 | | | | | | 216,015 | | | | | | 184,954 | | | | | | 151,157 | | | | | | 90,480 | | |
截至2019年6月30日的年度
|
| |
2020
|
| |
2019
|
| |
2018
|
| |
2017
|
| |
2016
|
| |||||||||||||||
| | |
(千)
|
| |||||||||||||||||||||||||||
净收入
|
| | | $ | 33,552 | | | | | $ | 54,713 | | | | | $ | 64,883 | | | | | $ | 64,615 | | | | | $ | 82,728 | | |
加号: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
利息费用净额
|
| | | | 12,856 | | | | | | 11,776 | | | | | | 11,910 | | | | | | 14,906 | | | | | | 16,592 | | |
所得税拨备(福利)
|
| | | | 21,960 | | | | | | 16,792 | | | | | | 23,187 | | | | | | 15,928 | | | | | | (5,967) | | |
折旧摊销
|
| | | | 32,341 | | | | | | 27,564 | | | | | | 26,943 | | | | | | 26,001 | | | | | | 23,452 | | |
EBITDA
|
| | | | 100,709 | | | | | | 110,845 | | | | | | 126,923 | | | | | | 121,450 | | | | | | 116,805 | | |
重组成本
|
| | | | 425 | | | | | | 6,281 | | | | | | — | | | | | | — | | | | | | — | | |
股票薪酬
|
| | | | 2,259 | | | | | | 2,259 | | | | | | 334 | | | | | | — | | | | | | — | | |
销售商品的收购相关成本
|
| | | | 280 | | | | | | — | | | | | | 1,671 | | | | | | — | | | | | | 2,566 | | |
与收购相关的应计薪酬
|
| | | | — | | | | | | — | | | | | | 1,152 | | | | | | 1,680 | | | | | | 1,680 | | |
与收购相关的交易成本
|
| | | | 462 | | | | | | 213 | | | | | | 400 | | | | | | 1,274 | | | | | | 618 | | |
与收购相关的其他,净额
|
| | | | (2,821) | | | | | | — | | | | | | (468) | | | | | | (972) | | | | | | — | | |
其他
|
| | | | — | | | | | | (1,506) | | | | | | — | | | | | | — | | | | | | — | | |
养老金结算费
|
| | | | — | | | | | | — | | | | | | — | | | | | | 1,702 | | | | | | — | | |
保险结算收益
|
| | | | — | | | | | | — | | | | | | — | | | | | | (7,500) | | | | | | — | | |
外币(收益)亏损,净额
|
| | | | 826 | | | | | | (55) | | | | | | (1,054) | | | | | | (113) | | | | | | (7,609) | | |
债务清偿损失
|
| | | | — | | | | | | — | | | | | | — | | | | | | 2,598 | | | | | | — | | |
调整后的EBITDA
|
| | | $ | 102,140 | | | | | $ | 118,037 | | | | | $ | 128,958 | | | | | $ | 120,119 | | | | | $ | 114,060 | | |
截至2019年6月30日的年度
|
| |
2020
|
| |
2019
|
| |
2018
|
| |
2017
|
| |
2016
|
| |||||||||||||||
| | |
(千)
|
| |||||||||||||||||||||||||||
EBITDA
|
| | | $ | 100,709 | | | | | $ | 110,845 | | | | | $ | 126,923 | | | | | $ | 121,450 | | | | | $ | 116,805 | | |
调整 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
重组成本
|
| | | | 425 | | | | | | 6,281 | | | | | | — | | | | | | — | | | | | | — | | |
股票薪酬
|
| | | | 2,259 | | | | | | 2,259 | | | | | | 334 | | | | | | — | | | | | | — | | |
销售商品的收购相关成本
|
| | | | 280 | | | | | | — | | | | | | 1,671 | | | | | | — | | | | | | 2,566 | | |
与收购相关的应计薪酬
|
| | | | — | | | | | | — | | | | | | 1,152 | | | | | | 1,680 | | | | | | 1,680 | | |
与收购相关的交易成本
|
| | | | 462 | | | | | | 213 | | | | | | 400 | | | | | | 1,274 | | | | | | 618 | | |
与收购相关的其他,净额
|
| | | | (2,821) | | | | | | — | | | | | | (468) | | | | | | (972) | | | | | | — | | |
其他
|
| | | | — | | | | | | (1,506) | | | | | | — | | | | | | — | | | | | | — | | |
养老金结算费
|
| | | | — | | | | | | — | | | | | | — | | | | | | 1,702 | | | | | | — | | |
保险结算收益
|
| | | | — | | | | | | — | | | | | | — | | | | | | (7,500) | | | | | | — | | |
外币(收益)亏损,净额
|
| | | | 826 | | | | | | (55) | | | | | | (1,054) | | | | | | (113) | | | | | | (7,609) | | |
债务清偿损失
|
| | | | — | | | | | | — | | | | | | — | | | | | | 2,598 | | | | | | — | | |
已支付利息
|
| | | | (11,577) | | | | | | (12,250) | | | | | | (11,208) | | | | | | (14,600) | | | | | | (14,215) | | |
缴纳所得税
|
| | | | (20,866) | | | | | | (16,215) | | | | | | (15,191) | | | | | | (14,762) | | | | | | (16,828) | | |
经营性资产、负债及其他项目变动
|
| | | | (10,349) | | | | | | (42,403) | | | | | | (32,551) | | | | | | 128 | | | | | | (45,799) | | |
保险结算提供的现金
|
| | | | — | | | | | | — | | | | | | — | | | | | | 7,500 | | | | | | — | | |
经营活动提供的净现金
|
| | | $ | 59,348 | | | | | $ | 47,169 | | | | | $ | 70,008 | | | | | $ | 98,385 | | | | | $ | 37,218 | | |
| | | | | | | | | | | | | | | | | | | | |
更改
|
| |||||||||||||||||||||
截至2019年6月30日的年度
|
| |
2020
|
| |
2019
|
| |
2018
|
| |
2020 / 2019
|
| |
2019 / 2018
|
| |||||||||||||||||||||||||||
| | |
(千元,每股除外)
|
| |||||||||||||||||||||||||||||||||||||||
净销售额
|
| | | $ | 800,354 | | | | | $ | 827,995 | | | | | $ | 819,982 | | | | | $ | (27,641) | | | | |
|
(3)%
|
| | | | $ | 8,013 | | | | |
|
1%
|
| |
毛利
|
| | | | 256,882 | | | | | | 264,624 | | | | | | 266,879 | | | | | | (7,742) | | | | |
|
(3)%
|
| | | | | (2,255) | | | | |
|
(1)%
|
| |
销售、一般和行政费用
|
| | | | 187,688 | | | | | | 181,398 | | | | | | 167,953 | | | | | | 6,290 | | | | |
|
3%
|
| | | | | 13,445 | | | | |
|
8%
|
| |
营业收入
|
| | | | 69,194 | | | | | | 83,226 | | | | | | 98,926 | | | | | | (14,032) | | | | |
|
(17)%
|
| | | | | (15,700) | | | | |
|
(16)%
|
| |
利息费用净额
|
| | | | 12,856 | | | | | | 11,776 | | | | | | 11,910 | | | | | | 1,080 | | | | |
|
9%
|
| | | | | (134) | | | | |
|
(1)%
|
| |
外币(收益)亏损,净额
|
| | | | 826 | | | | | | (55) | | | | | | (1,054) | | | | | | 881 | | | | |
|
*
|
| | | | | 999 | | | | |
|
*
|
| |
所得税前收入
|
| | | | 55,512 | | | | | | 71,505 | | | | | | 88,070 | | | | | | (15,993) | | | | |
|
(22)%
|
| | | | | (16,565) | | | | |
|
(19)%
|
| |
所得税拨备
|
| | | | 21,960 | | | | | | 16,792 | | | | | | 23,187 | | | | | | 5,168 | | | | |
|
31%
|
| | | | | (6,395) | | | | |
|
(28)%
|
| |
净收入
|
| | | $ | 33,552 | | | | | $ | 54,713 | | | | | $ | 64,883 | | | | | $ | (21,161) | | | | |
|
(39)%
|
| | | | $ | (10,170) | | | | |
|
(16)%
|
| |
每股净收益 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
基础版
|
| | | $ | 0.83 | | | | | $ | 1.35 | | | | | $ | 1.61 | | | | | $ | (0.52) | | | | | | | | | | | $ | (0.26) | | | | | | | | |
稀释
|
| | | $ | 0.83 | | | | | $ | 1.35 | | | | | $ | 1.61 | | | | | $ | (0.52) | | | | | | | | | | | $ | (0.26) | | | | | | | | |
加权平均流通股数量
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
基础版
|
| | | | 40,454 | | | | | | 40,412 | | | | | | 40,181 | | | | | | | | | | | | | | | | | | | | | | | | | | |
稀释
|
| | | | 40,504 | | | | | | 40,523 | | | | | | 40,385 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | |
更改
|
| |||||||||
截至2019年6月30日的年度
|
| |
2020
|
| |
2019
|
| |
2018
|
| |
2020 / 2019
|
| |
2019 / 2018
|
| |||||||||||||||
| | |
(千元,每股除外)
|
| |||||||||||||||||||||||||||
净销售额比率 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
毛利
|
| | |
|
32.1%
|
| | | |
|
32.0%
|
| | | |
|
32.5%
|
| | | | | | | | | | | | | |
销售、一般和行政费用
|
| | |
|
23.5%
|
| | | |
|
21.9%
|
| | | |
|
20.5%
|
| | | | | | | | | | | | | |
营业收入
|
| | |
|
8.6%
|
| | | |
|
10.1%
|
| | | |
|
12.1%
|
| | | | | | | | | | | | | |
所得税前收入
|
| | |
|
6.9%
|
| | | |
|
8.6%
|
| | | |
|
10.7%
|
| | | | | | | | | | | | | |
净收入
|
| | |
|
4.2%
|
| | | |
|
6.6%
|
| | | |
|
7.9%
|
| | | | | | | | | | | | | |
实际税率
|
| | |
|
39.6%
|
| | | |
|
23.5%
|
| | | |
|
26.3%
|
| | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | |
更改
|
| |||||||||||||||||||||
截至2019年6月30日的年度
|
| |
2020
|
| |
2019
|
| |
2018
|
| |
2020 / 2019
|
| |
2019 / 2018
|
| |||||||||||||||||||||||||||
| | |
(千)
|
| |||||||||||||||||||||||||||||||||||||||
净销售额 | | | | | | | | | |||||||||||||||||||||||||||||||||||
MFA和其他
|
| | | $ | 322,300 | | | | | $ | 350,468 | | | | | $ | 336,666 | | | | | $ | (28,168) | | | | |
|
(8)%
|
| | | | $ | 13,802 | | | | |
|
4%
|
| |
营养特产
|
| | | | 129,264 | | | | | | 113,215 | | | | | | 122,978 | | | | | | 16,049 | | | | |
|
14%
|
| | | | | (9,763) | | | | |
|
(8)%
|
| |
疫苗
|
| | | | 75,340 | | | | | | 68,291 | | | | | | 72,083 | | | | | | 7,049 | | | | |
|
10%
|
| | | | | (3,792) | | | | |
|
(5)%
|
| |
动物健康
|
| | | | 526,904 | | | | | | 531,974 | | | | | | 531,727 | | | | | | (5,070) | | | | |
|
(1)%
|
| | | | | 247 | | | | |
|
0%
|
| |
矿物质营养
|
| | | | 214,412 | | | | | | 233,782 | | | | | | 234,922 | | | | | | (19,370) | | | | |
|
(8)%
|
| | | | | (1,140) | | | | |
|
(0)%
|
| |
性能产品
|
| | | | 59,038 | | | | | | 62,239 | | | | | | 53,333 | | | | | | (3,201) | | | | |
|
(5)%
|
| | | | | 8,906 | | | | |
|
17%
|
| |
合计
|
| | | $ | 800,354 | | | | | $ | 827,995 | | | | | $ | 819,982 | | | | | $ | (27,641) | | | | |
|
(3)%
|
| | | | $ | 8,013 | | | | |
|
1%
|
| |
|
| | | | | | | | | | | | | | | | | | | | |
更改
|
| |||||||||||||||||||||
截至2019年6月30日的年度
|
| |
2020
|
| |
2019
|
| |
2018
|
| |
2020 / 2019
|
| |
2019 / 2018
|
| |||||||||||||||||||||||||||
| | |
(千)
|
| |||||||||||||||||||||||||||||||||||||||
调整后的EBITDA | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||||
动物健康
|
| | | $ | 123,106 | | | | | $ | 136,049 | | | | | $ | 141,914 | | | | | $ | (12,943) | | | | |
|
(10)%
|
| | | | $ | (5,865) | | | | |
|
(4)%
|
| |
矿物质营养
|
| | | | 14,678 | | | | | | 15,712 | | | | | | 18,583 | | | | | | (1,034) | | | | |
|
(7)%
|
| | | | | (2,871) | | | | |
|
(15)%
|
| |
性能产品
|
| | | | 4,534 | | | | | | 4,728 | | | | | | 1,881 | | | | | | (194) | | | | |
|
(4)%
|
| | | | | 2,847 | | | | |
|
151%
|
| |
企业
|
| | | | (40,178) | | | | | | (38,452) | | | | | | (33,420) | | | | | | (1,726) | | | | |
|
*
|
| | | | | (5,032) | | | | |
|
*
|
| |
合计
|
| | | $ | 102,140 | | | | | $ | 118,037 | | | | | $ | 128,958 | | | | | $ | (15,897) | | | | |
|
(13)%
|
| | | | $ | (10,921) | | | | |
|
(8)%
|
| |
调整后的EBITDA比率以细分净销售额
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
动物健康
|
| | |
|
23.4%
|
| | | |
|
25.6%
|
| | | |
|
26.7%
|
| | | | | | | | | | | | | | | | | | | | | | | | | |
矿物质营养
|
| | |
|
6.8%
|
| | | |
|
6.7%
|
| | | |
|
7.9%
|
| | | | | | | | | | | | | | | | | | | | | | | | | |
性能产品
|
| | |
|
7.7%
|
| | | |
|
7.6%
|
| | | |
|
3.5%
|
| | | | | | | | | | | | | | | | | | | | | | | | | |
公司(1)
|
| | |
|
(5.0)%
|
| | | |
|
(4.6)%
|
| | | |
|
(4.1)%
|
| | | | | | | | | | | | | | | | | | | | | | | | | |
总计(1)
|
| | |
|
12.8%
|
| | | |
|
14.3%
|
| | | |
|
15.7%
|
| | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | |
更改
|
| |||||||||||||||||||||
截至2019年6月30日的年度
|
| |
2020
|
| |
2019
|
| |
2018
|
| |
2020/ 2019
|
| |
2019 / 2018
|
| |||||||||||||||||||||||||||
| | |
(千)
|
| |||||||||||||||||||||||||||||||||||||||
净收入
|
| | | $ | 33,552 | | | | | $ | 54,713 | | | | | $ | 64,883 | | | | | $ | (21,161) | | | | |
|
(39)%
|
| | | | $ | (10,170) | | | | |
|
(16)%
|
| |
利息费用净额
|
| | | | 12,856 | | | | | | 11,776 | | | | | | 11,910 | | | | | | 1,080 | | | | |
|
9%
|
| | | | | (134) | | | | |
|
(1)%
|
| |
所得税拨备
|
| | | | 21,960 | | | | | | 16,792 | | | | | | 23,187 | | | | | | 5,168 | | | | |
|
31%
|
| | | | | (6,395) | | | | |
|
(28)%
|
| |
折旧和
摊销 |
| | | | 32,341 | | | | | | 27,564 | | | | | | 26,943 | | | | | | 4,777 | | | | |
|
17%
|
| | | | | 621 | | | | |
|
2%
|
| |
EBITDA
|
| | | | 100,709 | | | | | | 110,845 | | | | | | 126,923 | | | | | | (10,136) | | | | |
|
(9)%
|
| | | | | (16,078) | | | | |
|
(13)%
|
| |
重组成本
|
| | | | 425 | | | | | | 6,281 | | | | | | — | | | | | | (5,856) | | | | |
|
(93)%
|
| | | | | — | | | | |
|
*
|
| |
股票薪酬
|
| | | | 2,259 | | | | | | 2,259 | | | | | | 334 | | | | | | — | | | | |
|
0%
|
| | | | | 1,925 | | | | |
|
576%
|
| |
销售商品的收购相关成本
|
| | | | 280 | | | | | | — | | | | | | 1,671 | | | | | | 280 | | | | |
|
*
|
| | | | | (1,671) | | | | |
|
*
|
| |
与收购相关的应计薪酬
|
| | | | — | | | | | | — | | | | | | 1,152 | | | | | | — | | | | |
|
*
|
| | | | | (1,152) | | | | |
|
*
|
| |
与收购相关的交易成本
|
| | | | 462 | | | | | | 213 | | | | | | 400 | | | | | | 249 | | | | |
|
117%
|
| | | | | (187) | | | | |
|
(47)%
|
| |
与收购相关的其他,净额
|
| | | | (2,821) | | | | | | — | | | | | | (468) | | | | | | (2,821) | | | | |
|
*
|
| | | | | 468 | | | | |
|
*
|
| |
其他,净额
|
| | | | — | | | | | | (1,506) | | | | | | — | | | | | | 1,506 | | | | |
|
*
|
| | | | | (1,506) | | | | |
|
*
|
| |
外币(收益)亏损,净额
|
| | | | 826 | | | | | | (55) | | | | | | (1,054) | | | | | | 881 | | | | |
|
*
|
| | | | | 999 | | | | |
|
*
|
| |
调整后的EBITDA
|
| | | $ | 102,140 | | | | | $ | 118,037 | | | | | $ | 128,958 | | | | | $ | (15,897) | | | | |
|
(13)%
|
| | | | $ | (10,921) | | | | |
|
(8)%
|
| |
截至2019年6月30日的年度
|
| |
2019
|
| |
2018
|
| ||||||
| | |
(单位为千,不包括百分比)
|
| |||||||||
所得税拨备
|
| | | $ | 16,792 | | | | | $ | 23,187 | | |
实际所得税率
|
| | | | 23.5% | | | | | | 26.3% | | |
某些所得税项目 | | | | | | | | | | | | | |
受益于行使的员工股票期权
|
| | | $ | (310) | | | | | $ | (3,773) | | |
强制通行费
|
| | | | (360) | | | | | | 403 | | |
减少国内递延税金资产
|
| | | | — | | | | | | 2,289 | | |
减少境外递延税金资产
|
| | | | — | | | | | | 1,156 | | |
确认联邦和外国税收抵免
|
| | | | (1,417) | | | | | | (565) | | |
从累计其他综合收益中重新分类
|
| | | | — | | | | | | 527 | | |
释放未确认的税收优惠
|
| | | | (1,271) | | | | | | (994) | | |
合计
|
| | | $ | (3,358) | | | | | $ | (957) | | |
所得税拨备,不包括某些项目
|
| | | $ | 20,150 | | | | | $ | 24,144 | | |
不包括某些项目的有效所得税税率
|
| | | | 28.2% | | | | | | 27.4% | | |
| | | | | | | | | | | | | | | | | | | | |
更改
|
| |||||||||
截至2019年6月30日的年度
|
| |
2020
|
| |
2019
|
| |
2018
|
| |
2020 / 2019
|
| |
2019 / 2018
|
| |||||||||||||||
| | |
(千)
|
| |||||||||||||||||||||||||||
现金提供人/(使用于): | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
经营活动
|
| | | $ | 59,348 | | | | | $ | 47,169 | | | | | $ | 70,008 | | | | | $ | 12,179 | | | | | $ | (22,839) | | |
投资活动
|
| | | | (120,390) | | | | | | (14,133) | | | | | | (84,612) | | | | | | (106,257) | | | | | | 70,479 | | |
融资活动
|
| | | | 40,936 | | | | | | (4,107) | | | | | | (11,775) | | | | | | 45,043 | | | | | | 7,668 | | |
汇率变动对现金和现金等价物的影响
|
| | | | (1,124) | | | | | | (524) | | | | | | (536) | | | | | | (600) | | | | | | 12 | | |
现金和现金等价物净增加/(减少)
|
| | | $ | (21,230) | | | | | $ | 28,405 | | | | | $ | (26,915) | | | | | $ | (49,635) | | | | | $ | 55,320 | | |
| | | | | | | | | | | | | | | | | | | | |
更改
|
| |||||||||
截至2019年6月30日的年度
|
| |
2020
|
| |
2019
|
| |
2018
|
| |
2020 / 2019
|
| |
2019 / 2018
|
| |||||||||||||||
| | | | | | | | |
(千)
|
| |||||||||||||||||||||
EBITDA
|
| | | $ | 100,709 | | | | | $ | 110,845 | | | | | $ | 126,923 | | | | | $ | (10,136) | | | | | $ | (16,078) | | |
调整 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
重组成本
|
| | | | 425 | | | | | | 6,281 | | | | | | — | | | | | | (5,856) | | | | | | 6,281 | | |
股票薪酬
|
| | | | 2,259 | | | | | | 2,259 | | | | | | 334 | | | | | | — | | | | | | 1,925 | | |
销售商品的收购相关成本
|
| | | | 280 | | | | | | — | | | | | | 1,671 | | | | | | 280 | | | | | | (1,671) | | |
与收购相关的应计薪酬
|
| | | | — | | | | | | — | | | | | | 1,152 | | | | | | — | | | | | | (1,152) | | |
与收购相关的交易成本
|
| | | | 462 | | | | | | 213 | | | | | | 400 | | | | | | 249 | | | | | | (187) | | |
与收购相关的其他,净额
|
| | | | (2,821) | | | | | | — | | | | | | (468) | | | | | | (2,821) | | | | | | 468 | | |
其他,净额
|
| | | | — | | | | | | (1,506) | | | | | | — | | | | | | 1,506 | | | | | | (1,506) | | |
外币(收益)亏损,净额
|
| | | | 826 | | | | | | (55) | | | | | | (1,054) | | | | | | 881 | | | | | | 999 | | |
已支付利息,净额
|
| | | | (11,577) | | | | | | (12,250) | | | | | | (11,208) | | | | | | 673 | | | | | | (1,042) | | |
缴纳所得税
|
| | | | (20,866) | | | | | | (16,215) | | | | | | (15,191) | | | | | | (4,651) | | | | | | (1,024) | | |
经营性资产、负债及其他项目变动
|
| | | | (10,349) | | | | | | (42,403) | | | | | | (32,551) | | | | | | 32,054 | | | | | | (9,852) | | |
经营活动提供的净现金
|
| | | $ | 59,348 | | | | | $ | 47,169 | | | | | $ | 70,008 | | | | | $ | 12,179 | | | | | $ | (22,839) | | |
| | | | | | | | | | | | | | | | | | | | |
更改
|
| |||||||||
截至6月30日
|
| |
2020
|
| |
2019
|
| |
2018
|
| |
2020 / 2019
|
| |
2019 / 2018
|
| |||||||||||||||
| | |
(千为单位,比率除外)
|
| |||||||||||||||||||||||||||
现金和现金等价物以及短期投资
|
| | | $ | 91,343 | | | | | $ | 81,573 | | | | | $ | 79,168 | | | | | $ | 9,770 | | | | | $ | 2,405 | | |
营运资金
|
| | | | 222,006 | | | | | | 242,902 | | | | | | 205,651 | | | | | | (20,896) | | | | | | 37,251 | | |
流动资产与流动负债比率
|
| | | | 2.6:1 | | | | | | 2.71:1 | | | | | | 2.57:1 | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | |
更改
|
| |||||||||
截至6月30日
|
| |
2020
|
| |
2019
|
| |
2018
|
| |
2020/2019
|
| |
2019/2018
|
| |||||||||||||||
| | |
(千)
|
| |||||||||||||||||||||||||||
应收账款 - 交易
|
| | | $ | 126,522 | | | | | $ | 159,022 | | | | | $ | 135,742 | | | | | $ | (32,500) | | | | | $ | 23,280 | | |
DSO
|
| | | | 61 | | | | | | 70 | | | | | | 58 | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | |
更改
|
| |||||||||
截至6月30日
|
| |
2020
|
| |
2019
|
| |
2018
|
| |
2020/2019
|
| |
2019/2018
|
| |||||||||||||||
| | |
(千)
|
| |||||||||||||||||||||||||||
库存
|
| | | $ | 196,659 | | | | | $ | 198,322 | | | | | $ | 178,170 | | | | | $ | (1,663) | | | | | $ | 20,152 | | |
| | |
年
|
| | | | | | | |||||||||||||||||||||
| | |
在1个内
|
| |
超过1到3个
|
| |
3到5岁以上
|
| |
超过5个
|
| |
合计
|
| |||||||||||||||
| | |
(千)
|
| |||||||||||||||||||||||||||
长期债务(含本期部分)
|
| | | $ | 18,750 | | | | | $ | 200,000 | | | | | $ | — | | | | | $ | — | | | | | $ | 218,750 | | |
循环信贷安排
|
| | | | — | | | | | | 169,000 | | | | | | — | | | | | | — | | | | | | 169,000 | | |
利息支付
|
| | | | 10,726 | | | | | | 10,321 | | | | | | — | | | | | | — | | | | | | 21,047 | | |
租赁承诺额
|
| | | | 7,211 | | | | | | 8,942 | | | | | | 4,457 | | | | | | 6,869 | | | | | | 27,479 | | |
或有对价
|
| | | | — | | | | | | 4,840 | | | | | | — | | | | | | — | | | | | | 4,840 | | |
其他
|
| | | | 1,010 | | | | | | 1,822 | | | | | | 1,228 | | | | | | 1,123 | | | | | | 5,183 | | |
合同总义务
|
| | | $ | 37,697 | | | | | $ | 394,925 | | | | | $ | 5,685 | | | | | $ | 7,992 | | | | | $ | 446,299 | | |
| | |
季度
|
| |
年
|
| ||||||||||||||||||||||||
截至的期间
|
| |
09月30日
2019 |
| |
12月31日
2019 |
| |
3月31日
2020 |
| |
06月30日
2020 |
| |
06月30日
2020 |
| |||||||||||||||
| | |
(千)
|
| |||||||||||||||||||||||||||
净销售额 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
MFA和其他
|
| | | $ | 75,034 | | | | | $ | 91,955 | | | | | $ | 82,670 | | | | | $ | 72,641 | | | | | $ | 322,300 | | |
营养特色菜
|
| | | | 30,433 | | | | | | 33,062 | | | | | | 34,636 | | | | | | 31,133 | | | | | | 129,264 | | |
疫苗
|
| | | | 16,383 | | | | | | 18,672 | | | | | | 21,668 | | | | | | 18,617 | | | | | | 75,340 | | |
动物健康
|
| | | $ | 121,850 | | | | | $ | 143,689 | | | | | $ | 138,974 | | | | | $ | 122,391 | | | | | $ | 526,904 | | |
| | |
季度
|
| |
年
|
| ||||||||||||||||||||||||
截至的期间
|
| |
09月30日
2019 |
| |
12月31日
2019 |
| |
3月31日
2020 |
| |
06月30日
2020 |
| |
06月30日
2020 |
| |||||||||||||||
| | |
(千)
|
| |||||||||||||||||||||||||||
矿物质营养
|
| | | | 52,649 | | | | | | 55,685 | | | | | | 56,200 | | | | | | 49,878 | | | | | | 214,412 | | |
性能产品
|
| | | | 15,221 | | | | | | 14,638 | | | | | | 15,565 | | | | | | 13,614 | | | | | | 59,038 | | |
总净销售额
|
| | | | 189,720 | | | | | | 214,012 | | | | | | 210,739 | | | | | | 185,883 | | | | | | 800,354 | | |
销货成本
|
| | | | 132,057 | | | | | | 144,908 | | | | | | 141,188 | | | | | | 125,319 | | | | | | 543,472 | | |
毛利
|
| | | | 57,663 | | | | | | 69,104 | | | | | | 69,551 | | | | | | 60,564 | | | | | | 256,882 | | |
销售、一般和行政
费用 |
| | | | 47,516 | | | | | | 49,495 | | | | | | 48,232 | | | | | | 42,445 | | | | | | 187,688 | | |
营业收入
|
| | | | 10,147 | | | | | | 19,609 | | | | | | 21,319 | | | | | | 18,119 | | | | | | 69,194 | | |
利息费用净额
|
| | | | 3,354 | | | | | | 3,432 | | | | | | 3,263 | | | | | | 2,807 | | | | | | 12,856 | | |
外币(收益)亏损,净额
|
| | | | 3,221 | | | | | | (718) | | | | | | (608) | | | | | | (1,069) | | | | | | 826 | | |
所得税前收入
|
| | | | 3,572 | | | | | | 16,895 | | | | | | 18,664 | | | | | | 16,381 | | | | | | 55,512 | | |
所得税拨备(福利)
|
| | | | 1,057 | | | | | | 5,001 | | | | | | 5,163 | | | | | | 10,739 | | | | | | 21,960 | | |
净收入
|
| | | $ | 2,515 | | | | | $ | 11,894 | | | | | $ | 13,501 | | | | | $ | 5,642 | | | | | $ | 33,552 | | |
每股净收益 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
基础版
|
| | | $ | 0.06 | | | | | $ | 0.29 | | | | | $ | 0.33 | | | | | $ | 0.14 | | | | | $ | 0.83 | | |
稀释
|
| | | $ | 0.06 | | | | | $ | 0.29 | | | | | $ | 0.33 | | | | | $ | 0.14 | | | | | $ | 0.83 | | |
调整后的EBITDA | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
动物健康
|
| | | $ | 25,061 | | | | | $ | 33,838 | | | | | $ | 34,635 | | | | | $ | 29,572 | | | | | $ | 123,106 | | |
矿物质营养
|
| | | | 3,475 | | | | | | 3,684 | | | | | | 4,055 | | | | | | 3,464 | | | | | | 14,678 | | |
性能产品
|
| | | | 852 | | | | | | 1,457 | | | | | | 1,506 | | | | | | 719 | | | | | | 4,534 | | |
企业
|
| | | | (9,728) | | | | | | (10,491) | | | | | | (10,064) | | | | | | (9,895) | | | | | | (40,178) | | |
调整后的EBITDA
|
| | | $ | 19,660 | | | | | $ | 28,488 | | | | | $ | 30,132 | | | | | $ | 23,860 | | | | | $ | 102,140 | | |
净收入与调整后EBITDA的对账
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
净收入
|
| | | $ | 2,515 | | | | | $ | 11,894 | | | | | $ | 13,501 | | | | | $ | 5,642 | | | | | $ | 33,552 | | |
利息费用净额
|
| | | | 3,354 | | | | | | 3,432 | | | | | | 3,263 | | | | | | 2,807 | | | | | | 12,856 | | |
所得税拨备(福利)
|
| | | | 1,057 | | | | | | 5,001 | | | | | | 5,163 | | | | | | 10,739 | | | | | | 21,960 | | |
折旧摊销
|
| | | | 7,781 | | | | | | 8,148 | | | | | | 8,248 | | | | | | 8,164 | | | | | | 32,341 | | |
EBITDA
|
| | | | 14,707 | | | | | | 28,475 | | | | | | 30,175 | | | | | | 27,352 | | | | | | 100,709 | | |
重组成本
|
| | | | 425 | | | | | | — | | | | | | — | | | | | | — | | | | | | 425 | | |
股票薪酬
|
| | | | 565 | | | | | | 564 | | | | | | 565 | | | | | | 565 | | | | | | 2,259 | | |
销售商品的收购相关成本
|
| | | | 280 | | | | | | — | | | | | | — | | | | | | — | | | | | | 280 | | |
与收购相关的交易成本
|
| | | | 462 | | | | | | — | | | | | | — | | | | | | — | | | | | | 462 | | |
与收购相关的其他,净额
|
| | | | — | | | | | | 167 | | | | | | — | | | | | | (2,988) | | | | | | (2,821) | | |
外币(收益)亏损,净额
|
| | | | 3,221 | | | | | | (718) | | | | | | (608) | | | | | | (1,069) | | | | | | 826 | | |
调整后的EBITDA
|
| | | $ | 19,660 | | | | | $ | 28,488 | | | | | $ | 30,132 | | | | | $ | 23,860 | | | | | $ | 102,140 | | |
|
| | |
季度
|
| |
年
|
| ||||||||||||||||||||||||
截至的期间
|
| |
09月30日
2018 |
| |
12月31日
2018 |
| |
3月31日
2019 |
| |
06月30日
2019 |
| |
06月30日
2019 |
| |||||||||||||||
| | |
(千)
|
| |||||||||||||||||||||||||||
净销售额 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
MFA和其他
|
| | | $ | 87,004 | | | | | $ | 93,054 | | | | | $ | 84,095 | | | | | $ | 86,315 | | | | | $ | 350,468 | | |
营养特色菜
|
| | | | 26,970 | | | | | | 29,460 | | | | | | 28,227 | | | | | | 28,558 | | | | | | 113,215 | | |
疫苗
|
| | | | 17,215 | | | | | | 17,048 | | | | | | 16,867 | | | | | | 17,161 | | | | | | 68,291 | | |
动物健康
|
| | | $ | 131,189 | | | | | $ | 139,562 | | | | | $ | 129,189 | | | | | $ | 132,034 | | | | | $ | 531,974 | | |
矿物质营养
|
| | | | 54,838 | | | | | | 62,319 | | | | | | 60,653 | | | | | | 55,972 | | | | | | 233,782 | | |
性能产品
|
| | | | 14,126 | | | | | | 16,342 | | | | | | 15,894 | | | | | | 15,877 | | | | | | 62,239 | | |
总净销售额
|
| | | | 200,153 | | | | | | 218,223 | | | | | | 205,736 | | | | | | 203,883 | | | | | | 827,995 | | |
销货成本
|
| | | | 134,348 | | | | | | 149,579 | | | | | | 140,864 | | | | | | 138,580 | | | | | | 563,371 | | |
毛利
|
| | | | 65,805 | | | | | | 68,644 | | | | | | 64,872 | | | | | | 65,303 | | | | | | 264,624 | | |
销售、一般和行政
费用 |
| | | | 42,952 | | | | | | 42,938 | | | | | | 42,304 | | | | | | 53,204 | | | | | | 181,398 | | |
营业收入
|
| | | | 22,853 | | | | | | 25,706 | | | | | | 22,568 | | | | | | 12,099 | | | | | | 83,226 | | |
利息费用净额
|
| | | | 2,783 | | | | | | 3,015 | | | | | | 2,931 | | | | | | 3,047 | | | | | | 11,776 | | |
外币(收益)亏损,净额
|
| | | | (2,635) | | | | | | 2,617 | | | | | | 122 | | | | | | (159) | | | | | | (55) | | |
所得税前收入
|
| | | | 22,705 | | | | | | 20,074 | | | | | | 19,515 | | | | | | 9,211 | | | | | | 71,505 | | |
所得税拨备
|
| | | | 6,391 | | | | | | 5,326 | | | | | | 4,666 | | | | | | 409 | | | | | | 16,792 | | |
净收入
|
| | | $ | 16,314 | | | | | $ | 14,748 | | | | | $ | 14,849 | | | | | $ | 8,802 | | | | | $ | 54,713 | | |
每股净收益 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
基础版
|
| | | $ | 0.40 | | | | | $ | 0.37 | | | | | $ | 0.37 | | | | | $ | 0.22 | | | | | $ | 1.35 | | |
稀释
|
| | | $ | 0.40 | | | | | $ | 0.36 | | | | | $ | 0.37 | | | | | $ | 0.22 | | | | | $ | 1.35 | | |
调整后的EBITDA | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
动物健康
|
| | | $ | 35,716 | | | | | $ | 35,925 | | | | | $ | 33,241 | | | | | $ | 31,167 | | | | | $ | 136,049 | | |
矿物质营养
|
| | | | 2,563 | | | | | | 4,084 | | | | | | 5,287 | | | | | | 3,778 | | | | | | 15,712 | | |
性能产品
|
| | | | 716 | | | | | | 1,514 | | | | | | 1,330 | | | | | | 1,168 | | | | | | 4,728 | | |
企业
|
| | | | (8,886) | | | | | | (9,918) | | | | | | (9,850) | | | | | | (9,798) | | | | | | (38,452) | | |
调整后的EBITDA
|
| | | $ | 30,109 | | | | | $ | 31,605 | | | | | $ | 30,008 | | | | | $ | 26,315 | | | | | $ | 118,037 | | |
净收入与调整后EBITDA的对账
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
净收入
|
| | | $ | 16,314 | | | | | $ | 14,748 | | | | | $ | 14,849 | | | | | $ | 8,802 | | | | | $ | 54,713 | | |
利息费用净额
|
| | | | 2,783 | | | | | | 3,015 | | | | | | 2,931 | | | | | | 3,047 | | | | | | 11,776 | | |
所得税拨备
|
| | | | 6,391 | | | | | | 5,326 | | | | | | 4,666 | | | | | | 409 | | | | | | 16,792 | | |
折旧摊销
|
| | | | 6,691 | | | | | | 6,841 | | | | | | 6,875 | | | | | | 7,157 | | | | | | 27,564 | | |
EBITDA
|
| | | | 32,179 | | | | | | 29,930 | | | | | | 29,321 | | | | | | 19,415 | | | | | | 110,845 | | |
重组成本
|
| | | | — | | | | | | — | | | | | | — | | | | | | 6,281 | | | | | | 6,281 | | |
股票薪酬
|
| | | | 565 | | | | | | 564 | | | | | | 565 | | | | | | 565 | | | | | | 2,259 | | |
与收购相关的交易成本
|
| | | | — | | | | | | — | | | | | | — | | | | | | 213 | | | | | | 213 | | |
其他
|
| | | | — | | | | | | (1,506) | | | | | | — | | | | | | — | | | | | | (1,506) | | |
外币(收益)亏损,净额
|
| | | | (2,635) | | | | | | 2,617 | | | | | | 122 | | | | | | (159) | | | | | | (55) | | |
调整后的EBITDA
|
| | | $ | 30,109 | | | | | $ | 31,605 | | | | | $ | 30,008 | | | | | $ | 26,315 | | | | | $ | 118,037 | | |
|
|
独立注册会计师事务所报告
|
| | | | 84 | | |
|
截至2020年6月30日、2019年6月30日和2018年6月30日的财年合并经营报表
|
| | | | 86 | | |
|
截至2020年6月30日、2019年6月30日和2019年6月30日的财政年度合并全面收益表
2018 |
| | | | 87 | | |
|
截至2020年6月30日和2019年6月30日的合并资产负债表
|
| | | | 88 | | |
|
截至2020年6月30日、2019年6月30日和2018年6月30日的财政年度现金流量合并报表
|
| | | | 89 | | |
|
截至2020年6月30日的财年股东权益变动合并报表
2019年和2018年。 |
| | | | 90 | | |
|
截至2020年6月30日、2019年6月30日和2019年6月30日的财政年度合并财务报表附注
2018 |
| | | | 91 | | |
截至2019年6月30日的年度
|
| |
2020
|
| |
2019
|
| |
2018
|
| |||||||||
| | |
(千元,每股除外)
|
| |||||||||||||||
净销售额
|
| | | $ | 800,354 | | | | | $ | 827,995 | | | | | $ | 819,982 | | |
销货成本
|
| | | | 543,472 | | | | | | 563,371 | | | | | | 553,103 | | |
毛利
|
| | | | 256,882 | | | | | | 264,624 | | | | | | 266,879 | | |
销售、一般和行政费用
|
| | | | 187,688 | | | | | | 181,398 | | | | | | 167,953 | | |
营业收入
|
| | | | 69,194 | | | | | | 83,226 | | | | | | 98,926 | | |
利息费用净额
|
| | | | 12,856 | | | | | | 11,776 | | | | | | 11,910 | | |
外币(收益)亏损,净额
|
| | | | 826 | | | | | | (55) | | | | | | (1,054) | | |
所得税前收入
|
| | | | 55,512 | | | | | | 71,505 | | | | | | 88,070 | | |
所得税拨备
|
| | | | 21,960 | | | | | | 16,792 | | | | | | 23,187 | | |
净收入
|
| | | $ | 33,552 | | | | | $ | 54,713 | | | | | $ | 64,883 | | |
每股净收益 | | | | | | | | | | | | | | | | | | | |
基础版
|
| | | $ | 0.83 | | | | | $ | 1.35 | | | | | $ | 1.61 | | |
稀释
|
| | | $ | 0.83 | | | | | $ | 1.35 | | | | | $ | 1.61 | | |
加权平均已发行普通股 | | | | | | | | | | | | | | | | | | | |
基础版
|
| | | | 40,454 | | | | | | 40,412 | | | | | | 40,181 | | |
稀释
|
| | | | 40,504 | | | | | | 40,523 | | | | | | 40,385 | | |
截至2019年6月30日的年度
|
| |
2020
|
| |
2019
|
| |
2018
|
| |||||||||
| | |
(千)
|
| |||||||||||||||
净收入
|
| | | $ | 33,552 | | | | | $ | 54,713 | | | | | $ | 64,883 | | |
衍生工具公允价值变动
|
| | | | (12,854) | | | | | | (5,580) | | | | | | 2,300 | | |
外币折算调整
|
| | | | (32,513) | | | | | | (4,127) | | | | | | (23,542) | | |
未确认的养老金净收益(亏损)
|
| | | | (2,521) | | | | | | (1,837) | | | | | | (154) | | |
(拨备)所得税福利
|
| | | | 3,684 | | | | | | 1,846 | | | | | | 350 | | |
其他综合收益(亏损)
|
| | | | (44,204) | | | | | | (9,698) | | | | | | (21,046) | | |
综合收益(亏损)
|
| | | $ | (10,652) | | | | | $ | 45,015 | | | | | $ | 43,837 | | |
截至6月30日
|
| |
2020
|
| |
2019
|
| ||||||
| | |
(以千为单位,共享除外
和每股金额) |
| |||||||||
资产 | | | | | | | | | | | | | |
现金和现金等价物
|
| | | $ | 36,343 | | | | | $ | 57,573 | | |
短期投资
|
| | | | 55,000 | | | | | | 24,000 | | |
应收账款净额
|
| | | | 126,522 | | | | | | 159,022 | | |
库存,净额
|
| | | | 196,659 | | | | | | 198,322 | | |
其他流动资产
|
| | | | 37,313 | | | | | | 27,245 | | |
流动资产总额
|
| | | | 451,837 | | | | | | 466,162 | | |
物业、厂房和设备,净额
|
| | | | 148,109 | | | | | | 140,235 | | |
无形资产,净额
|
| | | | 70,997 | | | | | | 47,478 | | |
商誉
|
| | | | 52,679 | | | | | | 27,348 | | |
其他资产
|
| | | | 60,478 | | | | | | 45,448 | | |
总资产
|
| | | $ | 784,100 | | | | | $ | 726,671 | | |
负债和股东权益 | | | | | | | | | | | | | |
长期债务的当前部分
|
| | | $ | 18,750 | | | | | $ | 12,540 | | |
应付帐款
|
| | | | 66,091 | | | | | | 73,189 | | |
应计费用和其他流动负债
|
| | | | 72,397 | | | | | | 68,498 | | |
流动负债总额
|
| | | | 157,238 | | | | | | 154,227 | | |
循环信贷安排
|
| | | | 169,000 | | | | | | 96,000 | | |
长期债务
|
| | | | 199,257 | | | | | | 217,635 | | |
其他负债
|
| | | | 70,401 | | | | | | 42,794 | | |
总负债
|
| | | | 595,896 | | | | | | 510,656 | | |
承付款和或有事项(附注13) | | | | | | | | | | | | | |
普通股, 面值为每股0.0001美元;3亿股A类股
授权,2020年和2019年6月30日发行和发行的20,287,574股; 30,000,000股授权发行的B类股,20,166,034股已发行和已发行股票 2020年6月30日和2019年6月30日 |
| | | | 4 | | | | | | 4 | | |
优先股, 面值每股0.0001美元;授权1600万股,
未发行和发行任何股票 |
| | | | — | | | | | | — | | |
实收资本
|
| | | | 135,525 | | | | | | 133,266 | | |
留存收益
|
| | | | 183,060 | | | | | | 168,926 | | |
累计其他综合收益(亏损)
|
| | | | (130,385) | | | | | | (86,181) | | |
股东权益总额
|
| | | | 188,204 | | | | | | 216,015 | | |
总负债和股东权益
|
| | | $ | 784,100 | | | | | $ | 726,671 | | |
截至2019年6月30日的年度
|
| |
2020
|
| |
2019
|
| |
2018
|
| |||||||||
| | |
(千)
|
| |||||||||||||||
经营活动 | | | | | | | | | | | | | | | | | | | |
净收入
|
| | | $ | 33,552 | | | | | $ | 54,713 | | | | | $ | 64,883 | | |
将净收入与经营活动提供(使用)的净现金进行调整:
|
| | | | | | | | | | | | | | | | | | |
折旧摊销
|
| | | | 32,341 | | | | | | 27,564 | | | | | | 26,943 | | |
债务发行成本摊销
|
| | | | 882 | | | | | | 882 | | | | | | 883 | | |
股票薪酬
|
| | | | 2,259 | | | | | | 2,259 | | | | | | 334 | | |
与收购相关的项目
|
| | | | (2,433) | | | | | | — | | | | | | 3,908 | | |
递延所得税
|
| | | | 8,125 | | | | | | (105) | | | | | | 6,389 | | |
外币(收益)亏损,净额
|
| | | | (2,540) | | | | | | (1,899) | | | | | | (635) | | |
其他
|
| | | | 818 | | | | | | (302) | | | | | | 1,181 | | |
扣除业务收购后的营业资产和负债变动:
|
| | | | | | | | | | | | | | | | | | |
应收账款净额
|
| | | | 28,713 | | | | | | (23,679) | | | | | | (11,900) | | |
库存,净额
|
| | | | (12,930) | | | | | | (20,982) | | | | | | (24,292) | | |
其他流动资产
|
| | | | (11,137) | | | | | | (7,173) | | | | | | 134 | | |
其他资产
|
| | | | (2,121) | | | | | | (299) | | | | | | (152) | | |
应付帐款
|
| | | | (7,672) | | | | | | 12,092 | | | | | | 2,446 | | |
应计费用和其他负债
|
| | | | (8,509) | | | | | | 4,098 | | | | | | (114) | | |
经营活动提供的净现金
|
| | | | 59,348 | | | | | | 47,169 | | | | | | 70,008 | | |
投资活动 | | | | | | | | | | | | | | | | | | | |
购买短期投资
|
| | | | (80,000) | | | | | | (34,000) | | | | | | (82,000) | | |
短期投资期限
|
| | | | 49,000 | | | | | | 60,000 | | | | | | 32,000 | | |
资本支出
|
| | | | (34,045) | | | | | | (29,891) | | | | | | (18,548) | | |
业务收购
|
| | | | (54,549) | | | | | | (9,838) | | | | | | (15,000) | | |
其他,净额
|
| | | | (796) | | | | | | (404) | | | | | | (1,064) | | |
投资活动使用的净现金
|
| | | | (120,390) | | | | | | (14,133) | | | | | | (84,612) | | |
融资活动 | | | | | | | | | | | | | | | | | | | |
循环信贷借款
|
| | | | 243,000 | | | | | | 213,000 | | | | | | 225,000 | | |
循环信贷偿还
|
| | | | (170,000) | | | | | | (187,000) | | | | | | (220,000) | | |
支付长期债务和其他
|
| | | | (12,646) | | | | | | (12,649) | | | | | | (6,401) | | |
应付款收购单签发
|
| | | | — | | | | | | 3,775 | | | | | | — | | |
应付收购单付款
|
| | | | — | | | | | | (3,775) | | | | | | — | | |
普通股发行收益
|
| | | | — | | | | | | 1,134 | | | | | | 5,699 | | |
支付股息
|
| | | | (19,418) | | | | | | (18,592) | | | | | | (16,073) | | |
融资活动提供(使用)的净现金
|
| | | | 40,936 | | | | | | (4,107) | | | | | | (11,775) | | |
汇率变动对现金的影响
|
| | | | (1,124) | | | | | | (524) | | | | | | (536) | | |
现金及现金等价物净增(减)
|
| | | | (21,230) | | | | | | 28,405 | | | | | | (26,915) | | |
期初现金和现金等价物
|
| | | | 57,573 | | | | | | 29,168 | | | | | | 56,083 | | |
期末现金和现金等价物
|
| | | $ | 36,343 | | | | | $ | 57,573 | | | | | $ | 29,168 | | |
补充现金流信息 | | | | | | | | | | | | | | | | | | | |
已支付利息,净额
|
| | | $ | 11,577 | | | | | $ | 12,250 | | | | | $ | 11,208 | | |
已缴纳所得税,净额
|
| | | | 20,866 | | | | | | 16,215 | | | | | | 15,191 | | |
非现金投融资活动
|
| | | | | | | | | | | | | | | | | | |
物业、厂房和设备
|
| | | | 4,353 | | | | | | 2,890 | | | | | | 8,449 | | |
| | |
股份
常见 库存 |
| |
常见
库存 |
| |
首选
库存 |
| |
实收
大写 |
| |
保留
收入 |
| |
累计
其他 综合 收入(亏损) |
| |
合计
|
| |||||||||||||||||||||
截至2017年6月30日
|
| | | | 39,875,968 | | | | | $ | 4 | | | | | $ | — | | | | | $ | 123,840 | | | | | $ | 82,750 | | | | | $ | (55,437) | | | | | $ | 151,157 | | |
综合收益
(亏损) |
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 64,883 | | | | | | (21,046) | | | | | | 43,837 | | |
行使股票期权
|
| | | | 481,740 | | | | | | — | | | | | | — | | | | | | 5,699 | | | | | | — | | | | | | — | | | | | | 5,699 | | |
宣布的股息(每股0.40美元)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (16,073) | | | | | | — | | | | | | (16,073) | | |
股票薪酬费用
|
| | | | — | | | | | | — | | | | | | — | | | | | | 334 | | | | | | — | | | | | | — | | | | | | 334 | | |
截至2018年6月30日
|
| | | | 40,357,708 | | | | | $ | 4 | | | | | $ | — | | | | | $ | 129,873 | | | | | $ | 131,560 | | | | | $ | (76,483) | | | | | $ | 184,954 | | |
采用新的收入标准
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 1,245 | | | | | | — | | | | | | 1,245 | | |
综合收益
(亏损) |
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 54,713 | | | | | | (9,698) | | | | | | 45,015 | | |
行使股票期权
|
| | | | 95,900 | | | | | | — | | | | | | — | | | | | | 1,134 | | | | | | — | | | | | | — | | | | | | 1,134 | | |
宣布的股息(每股0.46美元)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (18,592) | | | | | | — | | | | | | (18,592) | | |
股票薪酬费用
|
| | | | — | | | | | | — | | | | | | — | | | | | | 2,259 | | | | | | — | | | | | | — | | | | | | 2,259 | | |
截至2019年6月30日
|
| | | | 40,453,608 | | | | | $ | 4 | | | | | $ | — | | | | | $ | 133,266 | | | | | $ | 168,926 | | | | | $ | (86,181) | | | | | $ | 216,015 | | |
综合收益
(亏损) |
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 33,552 | | | | | | (44,204) | | | | | | (10,652) | | |
宣布的股息(每股0.48美元)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (19,418) | | | | | | — | | | | | | (19,418) | | |
股票薪酬费用
|
| | | | — | | | | | | — | | | | | | — | | | | | | 2,259 | | | | | | — | | | | | | — | | | | | | 2,259 | | |
截至2020年6月30日
|
| | | | 40,453,608 | | | | | $ | 4 | | | | | $ | — | | | | | $ | 135,525 | | | | | $ | 183,060 | | | | | $ | (130,385) | | | | | $ | 188,204 | | |
截至2019年6月30日的年度
|
| |
2020
|
| |
2019
|
| |
2018
|
| |||||||||
净收入
|
| | | $ | 33,552 | | | | | $ | 54,713 | | | | | $ | 64,883 | | |
加权平均股数 - Basic
|
| | | | 40,454 | | | | | | 40,412 | | | | | | 40,181 | | |
股票期权和限制性股票单位的稀释效应
|
| | | | 50 | | | | | | 111 | | | | | | 204 | | |
加权平均 - 稀释股数
|
| | | | 40,504 | | | | | | 40,523 | | | | | | 40,385 | | |
每股净收益 | | | | | | | | | | | | | | | | | | | |
基础版
|
| | | $ | 0.83 | | | | | $ | 1.35 | | | | | $ | 1.61 | | |
稀释
|
| | | $ | 0.83 | | | | | $ | 1.35 | | | | | $ | 1.61 | | |
|
营运资金净额
|
| | | $ | 2,366 | | |
|
物业、厂房和设备
|
| | | | 2,005 | | |
|
固定的无形资产
|
| | | | 32,400 | | |
|
商誉
|
| | | | 25,331 | | |
|
获取的净资产
|
| | | $ | 62,102 | | |
截至2019年6月30日的年度
|
| |
2020
|
| |
2019
|
| |
2018
|
| |||||||||
动物健康 | | | | | | | | | | | | | | | | | | | |
MFA和其他
|
| | | $ | 322,300 | | | | | $ | 350,468 | | | | | $ | 336,666 | | |
营养特产
|
| | | | 129,264 | | | | | | 113,215 | | | | | | 122,978 | | |
疫苗
|
| | | | 75,340 | | | | | | 68,291 | | | | | | 72,083 | | |
总体动物健康
|
| | | $ | 526,904 | | | | | $ | 531,974 | | | | | | 531,727 | | |
矿物质营养
|
| | | | 214,412 | | | | | | 233,782 | | | | | | 234,922 | | |
性能产品
|
| | | | 59,038 | | | | | | 62,239 | | | | | | 53,333 | | |
合计
|
| | | $ | 800,354 | | | | | $ | 827,995 | | | | | $ | 819,982 | | |
截至2019年6月30日的年度
|
| |
2020
|
| |
2019
|
| |
2018
|
| |||||||||
美国
|
| | | $ | 471,938 | | | | | $ | 480,101 | | | | | $ | 490,880 | | |
拉丁美洲和加拿大
|
| | | | 158,939 | | | | | | 152,380 | | | | | | 143,231 | | |
欧洲、中东和非洲
|
| | | | 112,179 | | | | | | 105,365 | | | | | | 110,377 | | |
亚太地区
|
| | | | 57,298 | | | | | | 90,149 | | | | | | 75,494 | | |
合计
|
| | | $ | 800,354 | | | | | $ | 827,995 | | | | | $ | 819,982 | | |
截至2019年6月30日的年度
|
| |
2020
|
| |
2019
|
| |
2018
|
| |||||||||
利息费用净额 | | | | | | | | | | | | | | | | | | | |
定期贷款
|
| | | $ | 7,751 | | | | | $ | 8,553 | | | | | $ | 8,321 | | |
循环信贷安排
|
| | | | 5,317 | | | | | | 3,748 | | | | | | 2,777 | | |
债务发行成本摊销
|
| | | | 882 | | | | | | 882 | | | | | | 883 | | |
其他
|
| | | | 663 | | | | | | 494 | | | | | | 1,622 | | |
利息支出
|
| | | | 14,613 | | | | | | 13,677 | | | | | | 13,603 | | |
利息(收入)
|
| | | | (1,757) | | | | | | (1,901) | | | | | | (1,693) | | |
| | | | $ | 12,856 | | | | | $ | 11,776 | | | | | $ | 11,910 | | |
|
截至2019年6月30日的年度
|
| |
2020
|
| |
2019
|
| |
2018
|
| |||||||||
折旧摊销 | | | | | | | | | | | | | | | | | | | |
物业、厂房和设备折旧
|
| | | $ | 23,250 | | | | | $ | 21,423 | | | | | $ | 21,044 | | |
无形资产摊销
|
| | | | 8,869 | | | | | | 6,092 | | | | | | 5,851 | | |
其他资产摊销
|
| | | | 222 | | | | | | 49 | | | | | | 48 | | |
| | | | $ | 32,341 | | | | | $ | 27,564 | | | | | $ | 26,943 | | |
截至2019年6月30日的年度
|
| |
2020
|
| |
2019
|
| |
2018
|
| |||||||||
研发支出
|
| | | $ | 13,738 | | | | | $ | 12,093 | | | | | $ | 9,998 | | |
截至6月30日
|
| |
2020
|
| |
2019
|
| ||||||
应收账款净额 | | | | | | | | | | | | | |
应收贸易账款
|
| | | $ | 130,462 | | | | | $ | 163,464 | | |
坏账准备
|
| | | | (3,940) | | | | | | (4,442) | | |
| | | | $ | 126,522 | | | | | $ | 159,022 | | |
|
截至6月30日
|
| |
2020
|
| |
2019
|
| |
2018
|
| |||||||||
坏账准备 | | | | | | | | | | | | | | | | | | | |
期初余额
|
| | | $ | 4,442 | | | | | $ | 6,257 | | | | | $ | 6,428 | | |
坏账准备
|
| | | | 230 | | | | | | (201) | | | | | | 166 | | |
汇率变动的影响
|
| | | | (304) | | | | | | 38 | | | | | | (215) | | |
坏账核销
|
| | | | (428) | | | | | | (1,652) | | | | | | (122) | | |
期末余额
|
| | | $ | 3,940 | | | | | $ | 4,442 | | | | | $ | 6,257 | | |
|
截至6月30日
|
| |
2020
|
| |
2019
|
| ||||||
库存 | | | | | | | | | | | | | |
原材料
|
| | | $ | 73,837 | | | | | $ | 64,441 | | |
在制品
|
| | | | 8,881 | | | | | | 10,699 | | |
成品
|
| | | | 113,941 | | | | | | 123,182 | | |
| | | | $ | 196,659 | | | | | $ | 198,322 | | |
|
截至6月30日
|
| |
2020
|
| |
2019
|
| ||||||
物业、厂房和设备,净额 | | | | | | | | | | | | | |
土地
|
| | | $ | 9,796 | | | | | $ | 10,152 | | |
建筑和改善
|
| | | | 69,444 | | | | | | 71,036 | | |
机械设备
|
| | | | 267,805 | | | | | | 252,097 | | |
| | | | | 347,045 | | | | | | 333,285 | | |
累计折旧
|
| | | | (198,936) | | | | | | (193,050) | | |
| | | | $ | 148,109 | | | | | $ | 140,235 | | |
截至6月30日
|
| |
加权平均
使用寿命 (年) |
| |
2020
|
| |
2019
|
| ||||||
无形资产,净额 | | | | | | | | | | | | | | | | |
成本 | | | | | | | | | | | | | | | | |
技术
|
| |
12
|
| | | $ | 85,016 | | | | | $ | 71,016 | | |
产品注册、营销和分销权
|
| |
9
|
| | | | 17,795 | | | | | | 17,858 | | |
客户关系
|
| |
12
|
| | | | 31,089 | | | | | | 12,194 | | |
商品名称、商标和其他
|
| |
5
|
| | | | 3,857 | | | | | | 2,740 | | |
正在进行的研发
|
| | | | | | | — | | | | | | 1,800 | | |
| | | | | | | | 137,757 | | | | | | 105,608 | | |
累计摊销 | | | | | | | | | | | | | | | | |
技术
|
| | | | | | | (35,859) | | | | | | (29,333) | | |
产品注册、营销和分销权
|
| | | | | | | (17,770) | | | | | | (17,811) | | |
客户关系
|
| | | | | | | (10,336) | | | | | | (8,282) | | |
商品名称、商标和其他
|
| | | | | | | (2,795) | | | | | | (2,704) | | |
| | | | | | | | (66,760) | | | | | | (58,130) | | |
| | | | | | | $ | 70,997 | | | | | $ | 47,478 | | |
|
截至6月30日
|
| |
2020
|
| |
2019
|
| ||||||
商誉前滚 | | | | | | | | | | | | | |
期初余额
|
| | | $ | 27,348 | | | | | $ | 27,348 | | |
收购鱼鹰
|
| | | | 25,331 | | | | | | — | | |
期末余额
|
| | | $ | 52,679 | | | | | $ | 27,348 | | |
|
截至6月30日
|
| |
2020
|
| |
2019
|
| ||||||
其他资产 | | | | | | | | | | | | | |
ROU经营租赁资产
|
| | | $ | 22,873 | | | | | $ | — | | |
递延所得税
|
| | | | 11,430 | | | | | | 16,770 | | |
存款
|
| | | | 5,158 | | | | | | 7,024 | | |
保险投资
|
| | | | 5,801 | | | | | | 5,431 | | |
权益法投资
|
| | | | 4,219 | | | | | | 4,196 | | |
赔偿资产
|
| | | | 3,000 | | | | | | 3,000 | | |
发债成本
|
| | | | 1,021 | | | | | | 1,531 | | |
其他
|
| | | | 6,976 | | | | | | 7,496 | | |
| | | | $ | 60,478 | | | | | $ | 45,448 | | |
截至6月30日
|
| |
2020
|
| |
2019
|
| ||||||
应计费用和其他流动负债 | | | | | | | | | | | | | |
员工相关
|
| | | $ | 25,825 | | | | | $ | 28,298 | | |
当期经营租赁负债
|
| | | | 6,439 | | | | | | — | | |
佣金和返点
|
| | | | 5,782 | | | | | | 8,397 | | |
专业费
|
| | | | 5,766 | | | | | | 5,212 | | |
所得税和其他税
|
| | | | 3,821 | | | | | | 6,067 | | |
重组成本
|
| | | | 2,314 | | | | | | 3,590 | | |
保险相关
|
| | | | 1,272 | | | | | | 1,279 | | |
衍生品
|
| | | | 5,757 | | | | | | — | | |
其他
|
| | | | 15,421 | | | | | | 15,655 | | |
| | | | $ | 72,397 | | | | | $ | 68,498 | | |
|
2019年6月30日负债余额
|
| | | $ | 5,590 | | |
|
手续费
|
| | | | 425 | | |
|
付款
|
| | | | (3,155) | | |
|
2020年6月30日负债余额
|
| | | $ | 2,860 | | |
|
截至6月30日
|
| |
2020
|
| |
2019
|
| ||||||
其他负债 | | | | | | | | | | | | | |
长期经营租赁负债
|
| | | $ | 17,276 | | | | | $ | — | | |
长期递延所得税
|
| | | | 11,680 | | | | | | 8,978 | | |
衍生品
|
| | | | 7,691 | | | | | | 977 | | |
补充退休福利、递延补偿和其他
|
| | | | 8,067 | | | | | | 7,605 | | |
或有对价
|
| | | | 4,840 | | | | | | — | | |
国际退休计划
|
| | | | 5,499 | | | | | | 5,133 | | |
重组成本
|
| | | | 546 | | | | | | 2,000 | | |
美国养老金计划
|
| | | | 3,563 | | | | | | 3,934 | | |
其他长期负债
|
| | | | 11,239 | | | | | | 14,167 | | |
| | | | $ | 70,401 | | | | | $ | 42,794 | | |
|
截至6月30日
|
| |
2020
|
| |
2019
|
| ||||||
累计其他综合收益(亏损) | | | | | | | | | | | | | |
衍生工具
|
| | | $ | (13,448) | | | | | $ | (594) | | |
外币折算调整
|
| | | | (103,738) | | | | | | (71,225) | | |
未确认的养老金净收益(亏损)
|
| | | | (22,571) | | | | | | (20,050) | | |
(拨备)衍生工具所得税优惠
|
| | | | 3,256 | | | | | | 148 | | |
(拨备)长期公司间投资所得税优惠
|
| | | | 8,166 | | | | | | 8,166 | | |
(拨备)养老金收益(亏损)所得税收益
|
| | | | (2,050) | | | | | | (2,626) | | |
| | | | $ | (130,385) | | | | | $ | (86,181) | | |
截至6月
|
| |
2020
|
| |
2019
|
| ||||||
2022年6月到期的A期贷款
|
| | | $ | 218,750 | | | | | $ | 231,250 | | |
其他
|
| | | | — | | | | | | 40 | | |
| | | | | 218,750 | | | | | | 231,290 | | |
未摊销债务发行成本
|
| | | | (743) | | | | | | (1,115) | | |
| | | | | 218,007 | | | | | | 230,175 | | |
少:当前期限
|
| | | | (18,750) | | | | | | (12,540) | | |
| | | | $ | 199,257 | | | | | $ | 217,635 | | |
截至2019年6月30日的年度
|
| | | | | | |
2021
|
| | | | 18,750 | | |
2022
|
| | | | 200,000 | | |
合计
|
| | | $ | 218,750 | | |
截至6月30日
|
| |
2020
|
| |
资产负债表分类
|
| |||
资产: | | | | | | | | | | |
经营租赁ROU资产
|
| | | $ | 22,873 | | | | 其他资产 | |
负债: | | | | | | | | | | |
当前部分
|
| | | | 6,439 | | | |
应计费用和其他流动负债
|
|
非当前部分
|
| | | | 17,276 | | | | 其他负债 | |
营业租赁总负债
|
| | | $ | 23,715 | | | | | |
截至2019年6月30日的年度
|
| |
2020
|
| |||
经营租赁费用
|
| | | $ | 7,570 | | |
可变租赁费用
|
| | | | 1,304 | | |
短期租赁费
|
| | | | 802 | | |
租赁总费用
|
| | | $ | 9,676 | | |
|
截至2019年6月30日的年度
|
| |
2020
|
| |||
用于ROU运营租赁的运营现金流
|
| | | $ | 7,696 | | |
以新的经营租赁负债换取的使用权资产
|
| | | $ | 11,017 | | |
截至
|
| |
2020年6月30日
|
| |||
加权平均剩余租赁年限(以年为单位) - 净收益运营租赁
|
| | | | 6.49 | | |
加权平均贴现率 - 净收益经营租赁
|
| | | | 4.40% | | |
截至6月30日的年度
|
| | |||||
2021
|
| | | $ | 7,211 | | |
2022
|
| | | | 5,634 | | |
2023
|
| | | | 3,308 | | |
2024
|
| | | | 2,659 | | |
2025
|
| | | | 1,798 | | |
2026及以后
|
| | | | 6,869 | | |
租赁支付总额
|
| | | | 27,479 | | |
少:利息
|
| | | | 3,764 | | |
营业租赁总负债
|
| | | $ | 23,715 | | |
截至2019年6月30日的年度
|
| | | | | | |
2020
|
| | | $ | 5,815 | | |
2021
|
| | | | 4,160 | | |
2022
|
| | | | 3,191 | | |
2023
|
| | | | 1,445 | | |
2024
|
| | | | 865 | | |
此后
|
| | | | 765 | | |
最低租金总额
|
| | | $ | 16,241 | | |
截至6月30日
|
| |
2020
|
| |
2019
|
| | | | | | | |
2020
|
| |
2019
|
| ||||||||||||
| | |
授权共享
|
| |
面值
|
| |
已发行和流通股
|
| |||||||||||||||||||||
优先股
|
| | | | 16,000,000 | | | | | | 16,000,000 | | | | | $ | 0.0001 | | | | | | — | | | | | | — | | |
普通股 - A类
|
| | | | 300,000,000 | | | | | | 300,000,000 | | | | | $ | 0.0001 | | | | | | 20,287,574 | | | | | | 20,287,574 | | |
普通股 - B类
|
| | | | 30,000,000 | | | | | | 30,000,000 | | | | | $ | 0.0001 | | | | | | 20,166,034 | | | | | | 20,166,034 | | |
| | |
RSU
|
| |
授予日期
公允价值 每个RSU共享 |
| |
授予日期
公允价值 |
| |||||||||
2018年5月授予的基于性能的RSU
|
| | | | 200,000 | | | | | $ | 19.63 | | | | | $ | 3,926 | | |
2018年5月批准的基于时间的RSU
|
| | | | 50,000 | | | | | $ | 41.10 | | | | | $ | 2,055 | | |
出色的2020年6月30日和2019年6月
|
| | | | 250,000 | | | | | $ | 23.92 | | | | | $ | 5,981 | | |
截至2019年6月30日的年度
|
| |
2020
|
| |
2019
|
| ||||||
预计福利义务变更 | | | | | | | | | | | | | |
年初预计福利义务
|
| | | $ | 68,527 | | | | | $ | 61,557 | | |
利息成本
|
| | | | 2,112 | | | | | | 2,407 | | |
已支付福利
|
| | | | (2,000) | | | | | | (1,758) | | |
精算损失
|
| | | | 10,714 | | | | | | 6,321 | | |
年底预计福利义务
|
| | | $ | 79,353 | | | | | $ | 68,527 | | |
|
截至2019年6月30日的年度
|
| |
2020
|
| |
2019
|
| ||||||
计划资产变更 | | | | | | | | | | | | | |
年初计划资产公允价值
|
| | | $ | 64,593 | | | | | $ | 58,648 | | |
计划资产实际收益率
|
| | | | 10,821 | | | | | | 6,861 | | |
雇主缴费
|
| | | | 2,377 | | | | | | 842 | | |
已支付福利
|
| | | | (2,000) | | | | | | (1,758) | | |
年末计划资产公允价值
|
| | | $ | 75,791 | | | | | $ | 64,593 | | |
年底资金状况
|
| | | $ | (3,562) | | | | | $ | (3,934) | | |
截至2019年6月30日的年度
|
| |
2020
|
| |
2019
|
| ||||||
与养老金计划相关的累计其他综合收益(亏损) | | | | | | | | | | | | | |
期初余额
|
| | | $ | (20,050) | | | | | $ | (18,213) | | |
精算净损失和前期服务费用摊销
|
| | | | 515 | | | | | | 465 | | |
本期净精算(亏损)
|
| | | | (3,036) | | | | | | (2,302) | | |
净变化
|
| | | | (2,521) | | | | | | (1,837) | | |
期末余额
|
| | | $ | (22,571) | | | | | $ | (20,050) | | |
|
截至2019年6月30日的年度
|
| |
2020
|
| |
2019
|
| |
2018
|
| |||||||||
福利义务利息成本
|
| | | $ | 2,112 | | | | | $ | 2,407 | | | | | $ | 2,157 | | |
计划资产预期回报率
|
| | | | (3,144) | | | | | | (2,842) | | | | | | (3,236) | | |
精算净损失和前期服务费用摊销
|
| | | | 515 | | | | | | 465 | | | | | | 453 | | |
定期养老金净支出(收入)
|
| | | $ | (517) | | | | | $ | 30 | | | | | $ | (626) | | |
截至2019年6月30日的年度
|
| |
2020
|
| |
2019
|
| |
2018
|
| |||||||||
利息成本贴现率
|
| | | | 2.2% | | | | | | 3.1% | | | | | | 3.9% | | |
计划资产预期收益率
|
| | | | 4.9% | | | | | | 4.9% | | | | | | 5.6% | | |
年终福利债务贴现率
|
| | | | 2.8% | | | | | | 3.6% | | | | | | 4.2% | | |
截至2019年6月30日的年度
|
| | | | | | |
2021
|
| | | $ | 2,887 | | |
2022
|
| | | | 3,138 | | |
2023
|
| | | | 3,364 | | |
2024
|
| | | | 3,531 | | |
2025
|
| | | | 3,661 | | |
2026 – 2030
|
| | | | 19,789 | | |
| | |
目标
分配 |
| |
百分比
规划资产 |
| |||||||||
截至2019年6月30日的年度
|
| |
2021
|
| |
2020
|
| |
2019
|
| ||||||
债务证券
|
| |
57% – 77%
|
| | | | 66% | | | | | | 67% | | |
股权证券
|
| |
18% – 38%
|
| | | | 27% | | | | | | 28% | | |
全球资产配置/风险平价(1)
|
| |
0% – 15%
|
| | | | 5% | | | | | | 4% | | |
其他
|
| |
0% – 10%
|
| | | | 2% | | | | | | 1% | | |
| | |
使用
计量公允价值
|
| |||||||||||||||||||||
截至2020年6月30日
|
| |
一级
|
| |
二级
|
| |
第三级
|
| |
合计
|
| ||||||||||||
现金和现金等价物
|
| | | $ | 1,812 | | | | | $ | — | | | | | $ | — | | | | | $ | 1,812 | | |
共同-集体资金 | | | | | | | | | | | | | | | | | | | | | | | | | |
全球大盘股
|
| | | | — | | | | | | 16,678 | | | | | | 4,038 | | | | | | 20,716 | | |
固定收益证券
|
| | | | — | | | | | | 49,902 | | | | | | — | | | | | | 49,902 | | |
全球资产配置/风险平价
|
| | | | — | | | | | | 1,667 | | | | | | — | | | | | | 1,667 | | |
其他 | | | | | | | | | | | | | | | | | | | | | | | | | |
全球资产配置/风险平价
|
| | | | — | | | | | | — | | | | | | 1,669 | | | | | | 1,669 | | |
其他
|
| | | | — | | | | | | — | | | | | | 25 | | | | | | 25 | | |
| | | | $ | 1,812 | | | | | $ | 68,247 | | | | | $ | 5,732 | | | | | $ | 75,791 | | |
|
| | |
使用
计量公允价值
|
| |||||||||||||||||||||
截至2019年6月30日
|
| |
一级
|
| |
二级
|
| |
第三级
|
| |
合计
|
| ||||||||||||
现金和现金等价物
|
| | | $ | 215 | | | | | $ | — | | | | | $ | — | | | | | $ | 215 | | |
共同-集体资金 | | | | | | | | | | | | | | | | | | | | | | | | | |
全球大盘股
|
| | | | — | | | | | | 13,995 | | | | | | 4,016 | | | | | | 18,011 | | |
固定收益证券
|
| | | | — | | | | | | 43,288 | | | | | | — | | | | | | 43,288 | | |
全球资产配置/风险平价
|
| | | | — | | | | | | 1,446 | | | | | | — | | | | | | 1,446 | | |
其他 | | | | | | | | | | | | | | | | | | | | | | | | | |
全球资产配置/风险平价
|
| | | | — | | | | | | — | | | | | | 1,447 | | | | | | 1,447 | | |
其他
|
| | | | — | | | | | | — | | | | | | 186 | | | | | | 186 | | |
| | | | $ | 215 | | | | | $ | 58,729 | | | | | $ | 5,649 | | | | | $ | 64,593 | | |
3项资产的公允价值水平变动
|
| |
2020
|
| |
2019
|
| ||||||
期初余额
|
| | | $ | 5,649 | | | | | $ | 6,960 | | |
赎回
|
| | | | (49) | | | | | | (4,336) | | |
购买
|
| | | | 200 | | | | | | 2,800 | | |
公允价值变动
|
| | | | (68) | | | | | | 225 | | |
期末余额
|
| | | $ | 5,732 | | | | | $ | 5,649 | | |
截至2019年6月30日的年度
|
| |
2020
|
| |
2019
|
| |
2018
|
| |||||||||
国内
|
| | | $ | (3,142) | | | | | $ | 2,331 | | | | | $ | 19,819 | | |
外来
|
| | | | 58,654 | | | | | | 69,174 | | | | | | 68,251 | | |
所得税前收入
|
| | | $ | 55,512 | | | | | $ | 71,505 | | | | | $ | 88,070 | | |
|
截至2019年6月30日的年度
|
| |
2020
|
| |
2019
|
| |
2018
|
| |||||||||
当前拨备(福利): | | | | | | | | | | | | | | | | | | | |
联邦政府
|
| | | $ | (1,271) | | | | | $ | (459) | | | | | $ | 81 | | |
州和地方
|
| | | | 401 | | | | | | 102 | | | | | | 1,744 | | |
外来
|
| | | | 14,705 | | | | | | 16,603 | | | | | | 15,268 | | |
当前拨备总额
|
| | | | 13,835 | | | | | | 16,246 | | | | | | 17,093 | | |
延期拨备(福利): | | | | | | | | | | | | | | | | | | | |
联邦政府
|
| | | | 5,226 | | | | | | 858 | | | | | | 2,746 | | |
州和地方
|
| | | | 696 | | | | | | 432 | | | | | | 2,156 | | |
外来
|
| | | | 218 | | | | | | (691) | | | | | | 769 | | |
- 国外估值额度变化
|
| | | | 1,985 | | | | | | (53) | | | | | | 423 | | |
递延拨备(福利)总额
|
| | | | 8,125 | | | | | | 546 | | | | | | 6,094 | | |
所得税拨备
|
| | | $ | 21,960 | | | | | $ | 16,792 | | | | | $ | 23,187 | | |
截至2019年6月30日的年度
|
| |
2020
|
| |
2019
|
| |
2018
|
| |||||||||
联邦所得税税率
|
| | | | 21.0% | | | | | | 21.0% | | | | | | 28.1% | | |
扣除联邦福利后的州税和地方税
|
| | | | 1.7 | | | | | | 0.6 | | | | | | 1.5 | | |
外国所得税税率
|
| | | | 3.6 | | | | | | 4.1 | | | | | | (4.8) | | |
全球无形低税收入
|
| | | | 6.2 | | | | | | 0.8 | | | | | | — | | |
不确定税位的变化
|
| | | | 5.2 | | | | | | (1.0) | | | | | | 1.1 | | |
提高估值免税额
|
| | | | 3.6 | | | | | | — | | | | | | — | | |
确认联邦和外国税收抵免
|
| | | | (0.9) | | | | | | (2.5) | | | | | | (0.7) | | |
员工股票期权行权
|
| | | | — | | | | | | (0.4) | | | | | | (4.3) | | |
税法强制收取通行费
|
| | | | — | | | | | | (0.5) | | | | | | 0.5 | | |
递延税项资产减少
|
| | | | — | | | | | | — | | | | | | 3.9 | | |
其他
|
| | | | (0.8) | | | | | | 1.4 | | | | | | 1.0 | | |
实际税率
|
| | | | 39.6% | | | | | | 23.5% | | | | | | 26.3% | | |
截至6月30日
|
| |
2020
|
| |
2019
|
| ||||||
递延税金资产: | | | | | | | | | | | | | |
员工相关应计项目
|
| | | $ | 5,703 | | | | | $ | 5,735 | | |
库存
|
| | | | 726 | | | | | | 4,766 | | |
环境修复
|
| | | | 974 | | | | | | 1,128 | | |
净营业亏损结转 - 国内
|
| | | | 1,618 | | | | | | 902 | | |
净营业亏损结转 - 境外
|
| | | | 5,221 | | | | | | 3,703 | | |
经营性租赁负债
|
| | | | 5,732 | | | | | | — | | |
其他
|
| | | | 6,340 | | | | | | 6,302 | | |
| | | | | 26,314 | | | | | | 22,536 | | |
估值津贴
|
| | | | (3,403) | | | | | | (808) | | |
| | | | | 22,911 | | | | | | 21,728 | | |
递延纳税义务: | | | | | | | | | | | | | |
物业、厂房设备和无形资产
|
| | | | (6,108) | | | | | | (6,071) | | |
经营租赁ROU资产
|
| | | | (5,657) | | | | | | — | | |
其他
|
| | | | (921) | | | | | | (772) | | |
| | | | | (12,686) | | | | | | (6,843) | | |
递延税金净资产
|
| | | $ | 10,225 | | | | | $ | 14,885 | | |
截至6月30日
|
| |
2020
|
| |
2019
|
| ||||||
其他资产
|
| | | $ | 11,430 | | | | | $ | 16,770 | | |
其他负债
|
| | | | (1,205) | | | | | | (1,885) | | |
| | | | $ | 10,225 | | | | | $ | 14,885 | | |
截至6月30日
|
| |
2020
|
| |
2019
|
| |
2018
|
| |||||||||
期初余额
|
| | | $ | 808 | | | | | $ | 861 | | | | | $ | 438 | | |
所得税拨备
|
| | | | 2,595 | | | | | | (53) | | | | | | 423 | | |
期末余额
|
| | | $ | 3,403 | | | | | $ | 808 | | | | | $ | 861 | | |
截至6月30日
|
| |
2020
|
| |
2019
|
| |
2018
|
| |||||||||
未确认的税收优惠 - 期初
|
| | | $ | 6,343 | | | | | $ | 7,000 | | | | | $ | 6,553 | | |
税位更改 - 本期
|
| | | | 2,850 | | | | | | 528 | | | | | | 1,749 | | |
税位变动 - 前期,扣除与税务机关的结算
|
| | | | 108 | | | | | | (317) | | | | | | (994) | | |
诉讼时效失效
|
| | | | | | | | | | (1,053) | | | | | | — | | |
翻译
|
| | | | 206 | | | | | | 185 | | | | | | (308) | | |
未确认的税收优惠 - 期末
|
| | | | 9,507 | | | | | | 6,343 | | | | | | 7,000 | | |
利息和罚金 - 期末
|
| | | | 969 | | | | | | 750 | | | | | | 633 | | |
与不确定税位相关的总负债
|
| | | $ | 10,475 | | | | | $ | 7,093 | | | | | $ | 7,633 | | |
仪器
|
| |
对冲
|
| |
理论上的
金额为 2020年6月30日 |
| |
合并
资产负债表 |
| |
资产(负债)
截至 的公允价值 |
| ||||||||||||
|
06月30日
2020 |
| |
06月30日
2019 |
| ||||||||||||||||||||
选项
|
| |
巴西雷亚尔电话
|
| |
R$120,000
|
| | |
|
(1)
|
| | | | $ | 126 | | | | | $ | 413 | | |
选项
|
| |
巴西雷亚尔看跌期权
|
| |
R$120,000
|
| | |
|
(1)
|
| | | | $ | (3,900) | | | | | $ | (30) | | |
交换
|
| | 利率互换 | | |
$300,000
|
| | |
|
(2)
|
| | | | $ | (9,674) | | | | | $ | (977) | | |
截至2019年6月30日的年度
|
| |
已记录损益
在OCI中 |
| |
得(损)
在合并中确认 运营报表 |
| |
合并
的语句 运营 行项目合计 |
| |||||||||||||||||||||||||||||||||
仪器
|
| |
对冲
|
| |
2020
|
| |
2019
|
| |
合并
操作说明书 |
| |
2020
|
| |
2019
|
| |
2020
|
| |
2019
|
| ||||||||||||||||||
选项
|
| |
巴西雷亚尔电话
|
| | | $ | (4,157) | | | | | $ | 475 | | | |
销货成本
|
| | | $ | (115) | | | | | $ | 1,069 | | | | | $ | 543,472 | | | | | $ | 563,371 | | |
交换
|
| | 利率互换 | | | | $ | (8,697) | | | | | $ | (6,055) | | | |
利息费用净额
|
| | | $ | (310) | | | | | $ | 766 | | | | | $ | 12,856 | | | | | $ | 11,776 | | |
| | |
2020
|
| |
2019
|
| ||||||||||||||||||||||||||||||
截至6月30日
|
| |
一级
|
| |
二级
|
| |
第三级
|
| |
一级
|
| |
二级
|
| |
第三级
|
| ||||||||||||||||||
短期投资
|
| | | $ | 55,000 | | | | | $ | — | | | | | $ | — | | | | | $ | 24,000 | | | | | $ | — | | | | | $ | — | | |
外币衍生品
|
| | | $ | — | | | | | $ | (3,774) | | | | | $ | — | | | | | $ | — | | | | | $ | 383 | | | | | $ | — | | |
利率互换
|
| | | $ | — | | | | | $ | (9,674) | | | | | $ | — | | | | | $ | — | | | | | $ | (977) | | | | | $ | — | | |
收购的或有对价
|
| | | $ | — | | | | | $ | — | | | | | $ | (4,840) | | | | | $ | — | | | | | $ | — | | | | | $ | — | | |
| | |
06月30日
2020 |
| |||
2019年6月30日的余额
|
| | | $ | — | | |
收购鱼鹰
|
| | | | (7,553) | | |
货币时间价值增值
|
| | | | (275) | | |
公允价值调整
|
| | | | 2,988 | | |
2020年6月30日的余额
|
| | | $ | (4,840) | | |
截至2019年6月30日的年度
|
| |
2020
|
| |
2019
|
| |
2018
|
| |||||||||
净销售额 | | | | | | | | | | | | | | | | | | | |
动物健康
|
| | | $ | 526,904 | | | | | $ | 531,974 | | | | | $ | 531,727 | | |
矿物质营养
|
| | | | 214,412 | | | | | | 233,782 | | | | | | 234,922 | | |
性能产品
|
| | | | 59,038 | | | | | | 62,239 | | | | | | 53,333 | | |
总细分市场
|
| | | $ | 800,354 | | | | | $ | 827,995 | | | | | $ | 819,982 | | |
折旧摊销 | | | | | | | | | | | | | | | | | | | |
动物健康
|
| | | $ | 26,287 | | | | | $ | 22,312 | | | | | $ | 21,447 | | |
矿物质营养
|
| | | | 2,522 | | | | | | 2,319 | | | | | | 2,371 | | |
性能产品
|
| | | | 1,860 | | | | | | 1,127 | | | | | | 1,029 | | |
总细分市场
|
| | | $ | 30,669 | | | | | $ | 25,758 | | | | | $ | 24,847 | | |
调整后的EBITDA | | | | | | | | | | | | | | | | | | | |
动物健康
|
| | | $ | 123,106 | | | | | $ | 136,049 | | | | | $ | 141,914 | | |
矿物质营养
|
| | | | 14,678 | | | | | | 15,712 | | | | | | 18,583 | | |
性能产品
|
| | | | 4,534 | | | | | | 4,728 | | | | | | 1,881 | | |
总细分市场
|
| | | $ | 142,318 | | | | | $ | 156,489 | | | | | $ | 162,378 | | |
|
|
所得税前收入与调整后EBITDA的对账
|
| | | | | | | | | | | | | | | | | | |
|
所得税前收入
|
| | | $ | 55,512 | | | | | $ | 71,505 | | | | | $ | 88,070 | | |
|
利息费用净额
|
| | | | 12,856 | | | | | | 11,776 | | | | | | 11,910 | | |
|
折旧和摊销 - 总分部
|
| | | | 30,669 | | | | | | 25,758 | | | | | | 24,847 | | |
|
折旧和摊销 - 公司
|
| | | | 1,672 | | | | | | 1,806 | | | | | | 2,096 | | |
|
企业成本
|
| | | | 40,178 | | | | | | 38,452 | | | | | | 33,420 | | |
|
重组成本
|
| | | | 425 | | | | | | 6,281 | | | | | | — | | |
|
股票薪酬
|
| | | | 2,259 | | | | | | 2,259 | | | | | | 334 | | |
|
销售商品的收购相关成本
|
| | | | 280 | | | | | | — | | | | | | 1,671 | | |
|
与收购相关的应计薪酬
|
| | | | — | | | | | | — | | | | | | 1,152 | | |
|
与收购相关的交易成本
|
| | | | 462 | | | | | | 213 | | | | | | 400 | | |
|
与收购相关的其他,净额
|
| | | | (2,821) | | | | | | — | | | | | | (468) | | |
|
其他,净额
|
| | | | — | | | | | | (1,506) | | | | | | — | | |
|
外币(收益)亏损,净额
|
| | | | 826 | | | | | | (55) | | | | | | (1,054) | | |
|
调整后的EBITDA - 总分部
|
| | | $ | 142,318 | | | | | $ | 156,489 | | | | | $ | 162,378 | | |
|
截至6月30日
|
| |
2020
|
| |
2019
|
| ||||||
可识别资产 | | | | | | | | | | | | | |
动物健康
|
| | | $ | 560,663 | | | | | $ | 508,864 | | |
矿物质营养
|
| | | | 65,686 | | | | | | 67,662 | | |
性能产品
|
| | | | 31,016 | | | | | | 32,886 | | |
总细分市场
|
| | | | 657,365 | | | | | | 609,412 | | |
企业
|
| | | | 126,735 | | | | | | 117,259 | | |
合计
|
| | | $ | 784,100 | | | | | $ | 726,671 | | |
截至6月30日
|
| |
2020
|
| |
2019
|
| ||||||
物业、厂房和设备,净额 | | | | | | | | | | | | | |
美国
|
| | | $ | 59,778 | | | | | $ | 55,001 | | |
以色列
|
| | | | 54,041 | | | | | | 52,434 | | |
巴西
|
| | | | 14,771 | | | | | | 19,647 | | |
爱尔兰
|
| | | | 15,263 | | | | | | 9,409 | | |
其他
|
| | | | 4,256 | | | | | | 3,744 | | |
| | | | $ | 148,109 | | | | | $ | 140,235 | | |
| 展品:2.1* | | | 菲布罗动物健康公司作为买方,Osprey BioTechnics,Inc.作为公司,与Lauren Danielson和Vincent Scuilla作为卖方签署了截至2019年8月1日的资产购买协议(通过参考菲布罗动物健康公司于2019年4月11日提交的Form 10-Q季度报告的附件21.(文件编号001-36410)合并)。 | |
| 展品3.1 | | | 修改并重新发布的《菲布罗动物保健公司注册证书》(参考菲布罗动物保健公司2014年5月13日提交的《菲布罗动物保健公司10-Q季度报告附件3.1(文件编号001-36410)》)。 | |
| 展品#3.2 | | | 修改和重新修订菲布罗动物保健公司章程(通过引用菲布罗动物保健公司2014年5月13日提交的10-Q表格季度报告附件33.2(文件编号001-36410))。 | |
| 展品#4.1 | | | 菲布罗动物健康公司与BFI有限公司的注册权协议,日期为2014年4月16日(引用菲布罗动物健康公司于2014年3月31日提交的S-1/A表格注册说明书附件4.9(文件编号333-194467))。 | |
| 展品#4.2 | | | 根据1934年《证券交易法》第12节注册的证券说明(通过引用菲布罗动物健康公司2019年8月27日提交给美国证券交易委员会的2019年年报表格10-K(文件号:0001-36410)附件4.2中的内容而并入)。 | |
| 展品10.1 | | | 菲布罗动物健康公司、美国银行、N.A.和每一家贷款人之间于2017年6月29日签订的信贷协议(通过引用菲布罗动物健康公司于2017年6月29日提交给美国证券交易委员会的当前8-K报告附件10.1(文件编号001-36410))。 | |
| 展品10.2 | | | 撒玛利亚地毯有限公司和ABIC生物实验室有限公司之间于2011年1月26日签订的无保护租赁协议(引用菲布罗动物健康公司于2014年3月10日提交的S-1表格注册声明的附件10.17(文件第333-194467号))。 | |
| 展品#10.3 | | | 杰克·C·本德海姆和菲布罗动物健康公司之间于2014年3月27日签订的雇佣协议(通过引用菲布罗动物健康公司于2014年3月31日提交的S-1/A表格注册说明书第10.18号文件(文件第333-194467号)合并)。 | |
| 展品10.4 | | | 拉里·L·米勒和菲布罗动物健康公司之间于2008年5月2日发出的聘书,包括截至2008年5月2日的保密和保密、员工发明、竞业禁止协议(引用菲布罗动物健康公司于2014年3月10日提交的S-1表格注册说明书第10.20号附件(文件第333-194467号))。 | |
| 展品10.5 | | | 澄清拉里·L·米勒和菲布罗动物健康公司之间于2009年12月21日发出的就业邀请函修正案(合并内容参考菲布罗动物健康公司于2014年3月10日提交的S-1表格注册声明附件10.21(文件编号333-194467))。 | |
| 展品10.6 | | | 拉里·L·米勒(Larry L.Miller)和菲布罗动物健康公司(Phibro Animal Health Corporation)之间于2011年12月15日发出的就业邀请函修正案(合并内容参考菲布罗动物健康公司于2014年3月10日提交的S-1表格注册说明书第10.22号文件(文件编号333-194467))。 | |
| 展品10.7 | | | 菲布罗动物健康公司2008年奖励计划(通过引用菲布罗动物健康公司于2014年3月10提交的S-1表格注册说明书附件10.23(文件第333-194467号)合并)。 | |
| 展品10.8 | | | 菲布罗动物健康公司管理奖励计划(通过引用菲布罗动物健康公司2014年3月31日提交的S-1/A表格注册说明书附件10.24(文件第333-194467号)并入)。 | |
| 展品10.9 | | | 菲布罗动物健康公司退休收入和递延补偿计划,截至2009年4月15日修订并重述(引用菲布罗动物健康公司2014年3月10日提交的S-1表格注册说明书第10.25号文件(第333-194467号文件))。 | |
| 展品编号10.10 | | | 菲布罗动物健康公司高管收入递延补偿协议,日期为1990年3月1日(引用菲布罗动物健康公司2014年3月10日提交的S-1表格注册说明书附件10.26(文件编号333-194467))。 | |
| 展品编号10.11 | | | 2009年股票期权授予协议表格(参考菲布罗动物保健公司于2014年3月31日提交的S-1/A表格注册说明书附件10.28(文件编号333-194467))。 | |
| 展品编号10.12 | | | 2013年股票期权授予协议表格(引用菲布罗动物健康公司于2014年3月31日提交的S-1/A表格注册说明书附件10.29(文件编号333-194467))。 | |
| 展品#10.13 | | | 赔偿协议表格(引用菲布罗动物健康公司2014年4月4日提交的S-1/A表格注册说明书附件10.32(文件编号333-194467))。 | |
| 展品:10.14* | | | MJ Biologics,Inc.和Phibro Animal Health Corporation之间于2015年1月至20日签订的知识产权购买协议(通过引用Phibro Animal Health Corporation于2015年5月11日提交给美国证券交易委员会(Securities And Exchange Commission)的Form 10-Q季度报告附件10.33而并入)。 | |
| 展品:10.15* | | | 截至2015年1月至20日由MJ Biologics,Inc.和菲布罗动物健康公司起草的知识产权购买协议的第一修正案(通过引用菲布罗动物健康公司2018年11月6日提交给美国证券交易委员会的10-Q季度报告附件10.18(文件编号:0001-36410)合并)。 | |
| 展品编号10.16 | | | 限制性股票奖励协议表格(通过引用菲布罗动物健康公司于2018年5月7日提交给美国证券交易委员会的当前表格T8-K(文件编号13-1840497)附件10.2并入)。 | |
| 展品编号10.17 | | | 菲布罗动物健康公司和理查德·G·约翰逊之间于2015年5月11日签订的高管长期激励协议(通过引用菲布罗动物健康公司2015年年报10-K表的附件10.34并入,于2015年9月10日提交给美国证券交易委员会(文件编号001-36410))。 | |
| 展品编号10.18 | | | Rob Aukerman和Phibro Animal Health Corporation之间于2019年5月6日发出的聘书,包括保密和保密、员工发明以及竞业禁止和竞业禁止协议。 | |
| 展品编号21.1 | | | 菲布罗动物保健公司子公司列表。 | |
| 展品编号23.1 | | | 独立注册会计师事务所同意。 | |
| 展品编号31.1 | | | 首席执行官-根据2002年萨班斯-奥克斯利法案第302节进行认证。 | |
| 展品编号31.2 | | | 首席财务官-根据2002年萨班斯-奥克斯利法案认证 | |
| | | | 第302节。 | |
| 展品32.1** | | | 首席执行官-根据2002年萨班斯-奥克斯利法案第906节进行认证。 | |
| 展品32.2** | | | 首席财务官-根据2002年萨班斯-奥克斯利法案第906节进行认证。 | |
| 展品:101.INS* | | | XBRL实例文档。 | |
| 展品:101.SCH* | | | XBRL分类扩展架构文档。 | |
| 展品:101.CAL* | | | XBRL分类扩展计算链接库文档。 | |
| 展品:101.DEF* | | | XBRL分类扩展定义Linkbase文档。 | |
| 展品101.LAB* | | | XBRL分类扩展标签Linkbase文档。 | |
| 展品:101.PRE* | | | XBRL分类扩展演示文稿Linkbase文档。 | |
| | | | 菲布罗动物保健公司 | | |||
| 2020年8月26日 | | | 发件人: | | |
/s/Jack C.Bendheim
杰克·C·本德海姆
董事长、总裁兼首席执行官 |
|
| | | | 菲布罗动物保健公司 | | |||
| 2020年8月26日 | | | 发件人: | | |
/s/Jack C.Bendheim
杰克·C·本德海姆
董事长、总裁兼首席执行官 |
|
| 2020年8月26日 | | | 发件人: | | |
/s/理查德·G·约翰逊
理查德·G·约翰逊
首席财务官 |
|
| 2020年8月26日 | | | 发件人: | | |
/s/Daniel M.Bendheim
丹尼尔·M·本德海姆
董事兼执行副总裁, 企业战略 |
|
| 2020年8月26日 | | | 发件人: | | |
/s/Jonathan Bendheim
乔纳森·本德海姆
麦西地区总监兼总裁和 以色列业务部总经理 |
|
| 2020年8月26日 | | | 发件人: | | |
/s/Gerald K.Carlson
杰拉尔德·K·卡尔森
导演 |
|
| 2020年8月26日 | | | 发件人: | | |
/s/E.托马斯·柯克兰
E.Thomas Corcoran
导演 |
|
| 2020年8月26日 | | | 发件人: | | |
/s/Sam Gejdenon
Sam Gejdenon
导演 |
|
| 2020年8月26日 | | | 发件人: | | |
/s/Mary Lou Malanoski
玛丽·卢·马拉诺斯基
导演 |
|
| 2020年8月26日 | | | 发件人: | | |
/s/Carol A.Wrenn
卡罗尔·A·雷恩
导演 |
|